THE ROLE OF GLYOXALASE I IN HYPERGLYCEMIA-INDUCED SENSORY NEURON DAMAGE AND DEVELOPMENT OF DIABETIC SENSORY NEUROPATHY SYMPTOMS by Jack, Megan Marie
 
THE ROLE OF GLYOXALASE I IN HYPERGLYCEMIA-INDUCED SENSORY 
NEURON DAMAGE AND DEVELOPMENT OF DIABETIC SENSORY 
NEUROPATHY SYMPTOMS 
 
BY 
Megan Marie Jack 
 
Submitted to the graduate degree program in Anatomy and Cell Biology 
and the Graduate Faculty of the University of Kansas in partial fulfillment 
of the requirements for the degree of Doctor of Philosophy. 
 
 
______________________________________ 
Chairperson Douglas E. Wright, Ph.D. 
 
______________________________________ 
Dale R. Abrahamson, Ph.D. 
 
______________________________________ 
Lisa A. Stehno-Bittel, P.T., Ph.D. 
 
______________________________________ 
Russell Swerdlow, M.D. 
 
______________________________________ 
Mark A. Clements, M.D., Ph.D. 
 
Date Defended: July 19, 2011 
 
ii 
 
 
The Dissertation Committee for Megan Marie Jack certifies that this is the approved 
version of the following dissertation: 
 
THE ROLE OF GLYOXALASE I IN HYPERGLYCEMIA-INDUCED SENSORY 
NEURON DAMAGE AND DEVELOPMENT OF DIABETIC SENSORY 
NEUROPATHY SYMPTOMS 
 
 
Committee: 
 
 
______________________________________ 
Chairperson Douglas E. Wright, Ph.D. 
 
 
 
 
 
 
 
 
 
 
 
Date Approved:_________________ 
 
iii 
 
Abstract 
 Diabetic neuropathy is the most common and debilitating complication of 
diabetes mellitus with over half of all patients developing altered sensation as a result of 
damage to peripheral sensory neurons.  Hyperglycemia results in altered nerve 
conduction velocities, loss of epidermal innervation, and the development of painful or 
painless signs and symptoms in the feet and hands.  Current research has been unable to 
determine if a patient will develop insensate or painful neuropathy or be protected from 
peripheral nerve damage all together.  One of the mechanisms that has been recognized to 
have a role in the pathogenesis of sensory neuron damage is the process of reactive 
dicarbonyls forming advanced glycation endproducts (AGEs) as a direct result of 
hyperglycemia.  The glyoxalase system, composed of the enzymes glyoxalase I (GLO1) 
and glyoxalase II, is the main detoxification pathway involved in breaking down toxic 
reactive dicarbonyls before producing carbonyl stress and forming AGEs on proteins, 
lipids, or nucleic acids.  The purpose of this study was to explore a rol  for GLO1 in the 
development, progression, and/or prevention of diabetic neuropathy in animal mode s of 
diabetic neuropathy.  Initial studies characterized the pattern of expression of GLO1 in 
the peripheral nervous system and recognized restricted but variable expr ssion in 
peptidergic C-fibers responsible for nociception.  Diabetic mouse model of painful and 
insensate neuropathy showed reduced expression of GLO1 correlated with increased 
mechanical and thermal thresholds, while the strain with elevated GLO1 developed 
mechanical allodynia.  These results suggest an imbalance of fiber types, as a direct result 
of hyperglycemia damage, may influence the development of signs and symptoms of 
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neuropathy.  A study of two inbred substrains that vary in GLO1 abundance showed 
reduced GLO1 correlated with development of mechanical insensitivity, reduced 
epidermal innervation, and reduced expression of mitochondrial oxidative 
phosphorylation proteins.  Elevated GLO1 protected from these alterations.  Fi ally, 
methylglyoxal treatment of cultured adult sensory neurons resulted in reduced expression 
of electron transport chain proteins in certain strains.  Together, these studies suggest a 
protective role for GLO1 in preventing reactive dicarbonyl-mediate alterations of 
mitochondrial oxidative phosphorylation complexes and the development of insensate 
neuropathy. 
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Introduction 
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Diabetes Mellitus 
Diabetes mellitus is a chronic, multi-system metabolic disorder caused by a 
combination of environmental and genetic factors and characterized by hyperglycemia.  
Elevated blood glucose occurs due to either loss of insulin production by the pancreas or 
loss of peripheral utilization of insulin.  Though disordered glucose metabolism and 
altered insulin functionality are hallmarks of both types of diabetes mellitus, differences 
do underlie the development and clinical presentation each type.  Type I diabetes mellitus 
is an autoimmune disease that destroys insulin-producing pancreatic beta cells and 
typically manifests in either early childhood or young adulthood (van Belle, Coppieters et 
al. 2011).  On the other hand, Type II diabetes mellitus results from peripheral insulin 
resistance and relative insulin deficiency that typically manifests during middle or old age 
(Casey 2011).  Type II diabetes is often associated with obesity, reduced physical 
activity, and an unhealthy diet. 
The World Health Organization estimates that 220 million people world ide 
currently have diabetes.  Type II diabetes mellitus is the most prevalent form and 
accounts for 90-95% of these cases.  According to the Center for Disease Control and 
Prevention, 25.8 million children and adults currently suffer from diabetes mellitus in the 
United States.  Importantly, 35% of the adult population is estimated to have prediabetes 
or metabolic syndrome, a condition with higher than normal blood glucose and impaired 
insulin sensitivity that has yet to reach diagnostic criteria for diabetes mellitus (Centers 
for Disease Control and Prevention 2011).  Individuals with prediabetes are at  higher 
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potential for developing type II diabetes mellitus.  Hence, a staggering 79 million adults 
are at risk for developing type II diabetes mellitus.  Though typeI diabetes mellitus 
accounts for a far smaller percentage, 5-10% of cases, the incidence has been steadily 
rising in the past decades to nearly 5% annually in the United States (van Belle, 
Coppieters et al. 2011).  Hence, both type I and type II diabetes mellitus remain growing 
problems. 
Diabetic Neuropathy 
Classification and Prevalence 
Despite the differences in etiology, clinical presentation, and disease prevalence, 
secondary complications, such as heart disease, stroke, retinopathy, nep ropathy, and 
neuropathy, occur in both type I and II diabetes mellitus.  Due to the continual rise in 
diabetes mellitus, secondary complications continue to be a large economic burden in the 
United States and across the world (Said 2007).  Of these, diabetic neuropathy is the most 
common complication of long-term diabetes mellitus (Vinik, Park et al. 2000; Said 2007; 
Edwards, Vincent et al. 2008).  The Center for Disease Control and Prevention estimates 
60-70% of diabetic patients will develop diabetic neuropathy symptoms with the 
prevalence increasing with the duration of diabetes mellitus (Figure 1) (Centers for 
Disease Control and Prevention 2011).  Patients with diabetic neuropathy are at an 
increased risk for developing ulcers, recurrent foot infections, and Charcot joints, bony 
destruction and deformation due to repetitive, traumatic injury, often associated with 
reduced sensation in the feet (Vinik, Park et al. 2000; Little, Edwards et al. 2007)
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Figure 1: The prevalence of diabetic peripheral neuropathy as a consequence of both 
Type I and Type II diabetes mellitus suggests at least half of all diabetic patients will 
develop sensory signs and symptoms.  The development of diabetic neuropathy is 
thought to be a direct consequence of hyperglycemia.  Consequently, the incidence of 
diabetic neuropathy also increases with the duration of diabetes.  Adapted from Edwards 
J.L., et al., 2008, Pharmacol Ther 120(1):1-34. 
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Consequently, diabetic neuropathy is the cause of 50-75% of non-traumatic a putations 
(Vinik, Park et al. 2000).  Diabetic neuropathy has a profound impact on patie ts’ quality 
of life and is responsible for majority of diabetes-associated morbidity and mortality. 
Diabetic neuropathy is a collection of syndromes, either focal or diffuse in nature, 
affecting sensory, motor, and/or autonomic peripheral neurons (Vinik, Par  et al. 2000; 
Edwards, Vincent et al. 2008).  These disorders can range from clinical to subclinical and 
differ in their anatomical distribution, clinical course, and spectrum of symptoms.  The 
most prevalent of the syndromes is distal symmetrical sensorimot r polyneuropathy, 
often referred to as diabetic peripheral neuropathy, that results from damage to peripheral 
sensory nerves and accounts for nearly 80% of diabetic neuropathy cases (Said 2007).  
Diabetes-induced nerve damage causes a dying-back of distal axons that begins in the 
feet and progresses proximally in a stocking-and-glove distribution (DCCT 1993; 
Zochodne, Ramji et al. 2008).  Diabetic peripheral neuropathy has an in idious onset and 
is chronic and progressive in nature; therefore, often results in evere, irreversible 
symptoms after longstanding diabetes mellitus. 
Clinical and Pathological Features 
 The hallmark of diabetic neuropathy is the symmetrical loss of distal skin 
innervation due to dying-back of small cutaneous nerve fibers.  Sural nerve biopsies from 
diabetic patients also demonstrate loss of unmyelinated C-fibers and mall myelinated Aδ 
fibers in early stages of diabetic neuropathy with progressive in olvement of large 
myelinated Aβ fibers with duration of disease (Said, Slama et al. 1983; Yagihashi, 
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Yamagishi et al. 2007).  Despite histological and ultrastructural findings of axonal 
regeneration, collateral sprouting, and remyelination within peripheral nerves (Malik, 
Tesfaye et al. 2005), impaired nerve regeneration has been documented (Kennedy and 
Zochodne 2000; Kennedy and Zochodne 2005).  However, regeneration is ultimately 
unable to compensate for the continued vicious cycle of damage and neurodeg neration 
of sensory neurons (Vincent, Russell et al. 2004; Kennedy and Zochodne 2005).   
While neurons are clear targets of diabetes-induced damage, other cell types 
present in the nerve do not escape the insult.  Distal axonopathy and neuronal loss are 
accompanied by segmental demyelination, the loss of myelinating Schwann cells over 
segments of the axon (Sima, Nathaniel et al. 1988).  Other prominent features of diabetic 
nerves are abnormalities and degeneration of the nodal and paranodal appar tus.  Marked 
paranodal swelling precedes demyelination which alters the nodes of Ranvier and normal 
saltatory conduction (Sima, Nathaniel et al. 1988).  Endoneurial capillaries are also 
susceptible to the damaging effects of diabetes.  As a result, it has been suggested that 
neuronal ischemia may be a contributing factor to diabetic polyneuropathy.  Biopsies 
from diabetic patients show thickening of the endothelial basement membrane, 
endothelial cell hyperplasia, and narrowing of the capillary lumen (Malik, Tesfaye et al. 
2005).   
 Diabetes-induced damage results in peripheral nerve pathology that correlates 
with clinical signs and symptoms.  Nerve injury that results in tructural changes can be 
measured through clinical neurological assessment, quantitative sensory testing, nerve 
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conduction studies, and peripheral nerve biopsies that are often used in combination to 
diagnose diabetic neuropathy.  Diabetic patients are routinely screened with a battery of 
clinical tests, including responses to a pinprick, tuning fork vibration, and 10 g 
monofilament and evaluation of ankle reflexes, each of which access various sensory 
modalities (Pambianco, Costacou et al. 2011).  The gold standard for diagnosing diabetic 
polyneuropathy is electrophysiological studies that include sensory (SNCV) and motor 
nerve conduction velocity (MNCV) as well as compound sensory nerve action potentials 
(SNAPs) and motor action potentials (CMAPs) (Arezzo and Zotova 2002; England, 
Gronseth et al. 2005).  Structural alterations typically result in mild to moderate slowing 
of motor and sensory nerve conduction velocities as well as reduced amplitudes of 
evoked potentials indicative of both Schwannopathy and myelinated fiber axonopathy 
(Zochodne 1999; Kles and Bril 2006).  More in-depth, quantitative sensory testing that 
measures vibration, thermal, and pain perception thresholds can also be used to detect 
and monitor the progression of diabetic neuropathy, particularly small fiber dysfunction 
(Gibbons and Freeman 2004).  
The clinical features of diabetic neuropathy can be divided based on the type of 
fibers that are damaged and lost.  Impairment of small, myelinatd Aδ fibers and 
unmyelinated C-fibers results in altered mechanical, thermal, and pain sensation.  Deficits 
in vibration, proprioception, and balance are often a consequence of large, myelinated Aβ 
fiber damage. Sensory symptoms usually predominate in diabetic peripheral neuropathy 
(Sinnreich, Taylor et al. 2005), although with progression of the disease, motor 
dysfunction may also be present (Zochodne 1999).   
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The majority of patients experience insensate neuropathy characterized by 
painless symptoms including reduced vibratory perception, numbness, and insensitivity 
to touch and pain.  However, others have painful diabetic neuropathy that manifests as 
positive symptoms of hyperalgesia, tactile allodynia, paresthesias, abnormal sensitivity to 
temperature, and unremitting pain (Sugimoto, Murakawa et al. 2000; Obrosova 2009).  
Data on the prevalence of painful diabetic has varied widely with some reporting a 
prevalence rate of 7-20% (Tesfaye and Kempler 2005) and others reporting 40-50% of 
those with diabetic neuropathy having neuropathic complications.  The European 
Diabetes (EURODIAB) prospective study found approximately 25% of type I diabetic 
patients developed painful symptoms throughout the course of the 7-year inv stigation 
(Tesfaye and Kempler 2005).  
Although there is a considerable understanding of the molecular and pathological 
process responsible for damage to the peripheral nervous system that will be discussed in 
detail below, the mechanisms that produce painful versus insensate signs and symptoms 
are not known.  Furthermore, neurophysiological and histological findings do not 
distinguish between patients suffering with positive and negative symptoms (Malik, 
Veves et al. 2001).  The mechanisms underlying the development of these dichotomous 
symptoms remain a significant question that must be addressed to enable the 
development of improved and targeted therapies for diabetic neuropathy.  
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Pathogenesis 
Though the precise reason the peripheral nervous system is targeted in diabetes 
mellitus remains unclear, sensory neurons appear particularly susceptible to prolonged 
hyperglycemia potentially due to a number of inherent anatomical, physiological, and 
structural characteristics.  First, the peripheral nervous system exists outside the relatively 
protective blood-nerve and blood-brain barrier rendering them more vulnerable to the 
metabolic insults of diabetes mellitus (McHugh and McHugh 2004).  Due to their high 
energy requirements, neurons do not rely on insulin stimulation for glucose uptake 
(Tomlinson and Gardiner 2008); hence, glucose concentrations in sensory neurons mirror 
plasma concentrations (McHugh and McHugh 2004).  Consequently, dorsal root ganglion 
(DRG) neurons are continually exposed to damaging levels of glucose, particularly in 
uncontrolled diabetes mellitus (Tomlinson and Gardiner 2008).  Furthermore, the unique 
structure of peripheral neurons, particularly in the feet and hands, may render these cells 
more vulnerable to metabolic alterations and diabetes-induced structural damage.  
Majority of the cellular mass exists in the axon that can stretch several meters from the 
soma.  Peripheral neurons are heavily reliant on transport of cellular components for 
maintenance and normal functioning of peripheral processes.  Consequently, damage to 
the neuronal cell body and/or axons hinders cellular transport and compromises support 
and maintenance of peripheral innervation (Zochodne, Ramji et al. 2008). 
 Though the pathogenesis of diabetic neuropathy is likely multifactori l, all the 
mechanisms that have been implicated in nerve damage are a direct or indirect 
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consequence of prolonged hyperglycemia (Figure 2).  In fact, the only effective treatment 
at reducing the risk and/or delaying progression of diabetic neuropathy is maintenance of 
near-normal blood glucose levels (DCCT 1993).  Consequently, animal and in vitro 
experiments have focused on identifying metabolic pathways involved in the 
development of diabetic neuropathy in the peripheral nervous system.  It is also important 
to highlight dysfunction of these biochemical pathways also occurs in endothelial cells 
and Schwann cells that can cause nerve ischemia and altered nerve function, which have 
been implicated in the disease process.   
As glucose levels rise within sensory neurons due to hyperglycmia, normal 
metabolic pathways become overwhelmed and excess glucose is shunted into other 
ancillary pathways that under these conditions become damaging.  Excess glucose is 
initially converted to sorbitol by the enzyme aldose reductase.  Increased sorbitol is 
thought to promote osmotic stress within the neuron itself and also by depleting other 
intracellular osmolytes that have secondary roles as cell signalin  molecules (Tomlinson 
and Gardiner 2008).   On the other hand others think sorbitol does not pose an osmotic
challenge to the neuron because levels are far lower than other glucose metabolites 
(Sheetz and King 2002; Duby, Campbell et al. 2004).  While some debate exists about the 
role of sorbitol as an osmolyte, increased flux through the polyol pathway does deplete 
NADPH, a reducing agent necessary for the production of glutathione, which results in 
reduced antioxidant defenses and increased oxidative stress (Vincent, Russellet al. 2004). 
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Figure 2: A schematic outlining the proposed pathogenic mechanisms that have been 
implicated in the development of diabetic neuropathy.  Hyperglycemia produces glucose 
toxicity by shunting glucose and its metabolites into other metabolic pathways.  These 
include increased polyol pathway flux, elevated protein kinase C activation, increased 
hexosamine pathway signaling, heightened protein glycation, and oxidative stress.  These 
metabolic derangements can impact all of the components of the peripheral nerve 
including sensory and motor neurons, endothelial cells in the vasculature, nd Schwann 
cells.  .  Adapted from Edwards J.L., et al., 2008, Pharmacol Ther 120(1):1-34 and 
Brownlee, M., 2005, Diabetes 54(6): 1615-25. 
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Figure 2 
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Two other pathways that have been implicated in the development of diabetic 
neuropathy are the hexosamine and protein kinase C (PKC) pathways (Figure 2).  Their 
pathological role has been primarily investigated in endothelial cells and microvascular 
complications (Das Evcimen and King 2007).  It is important to note that reduced 
endoneurial blood flow has also been implicated in the development of diabetic 
complications highlighting that dysfunction also occurs in the vasculature (Das Evcimen 
and King 2007; Geraldes and King 2010).  Both of these pathways result in altered gene 
expression that promotes contractility, reduced flow, and inflammation resulting in nerve 
ischemia (Das Evcimen and King 2007; Edwards, Vincent et al. 2008; Madonn  and De 
Caterina 2011).   
Due to a combination of increased glycolysis and reduced activity of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), both glyceradehyde 3-phosphate 
and dihydroxyacetone phosphate (DHAP) build up in the neuron.  Under normal 
conditions, low levels of these metabolites are converted to methylglyoxal.  However, 
under hyperglycemic conditions, concentrations of methylglyoxal increase within the 
neuron due to the nonezymatic breakdown of these two glycolytic intermediates (Phillips 
and Thornalley 1993; Thornalley 1996).  Elevated levels of methylglyoxa  as well as 
other sugars, such as fructose, lead to the formation of advanced glycation endproducts 
(AGEs).  AGEs modify cellular components, signal through the receptor for advanced 
glycation endproducts (RAGE), and compromise normal neuronal function.  This 
pathway and its role in the pathogenesis of diabetic neuropathy will be covered in more 
detail. 
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Oxidative stress has become an emerging theme that has been suggested to 
incorporate dysfunction in the seemingly discrete metabolic pathways discussed above 
and unify them into a common pathogenic mechanism (Brownlee 2001; Vincent, Russell 
et al. 2004; Brownlee 2005).  Increased glycolysis ultimately results in excess products 
from the citric acid cycle, NADH and FADH2.  This increase in energy-substrate 
overloads and slows the electron transfer chain which allows for escape of electrons and 
the production of reactive oxygen species (ROS) (Vincent, Russell et al. 2004).  
Oxidative damage and reduced antioxidant capacity critically impair sensory neurons’ 
function and is purported to contribute to signs and symptoms of diabetic neuropathy 
(Zochodne 1999; Duby, Campbell et al. 2004; Vincent, Russell et al. 2004). 
Rodent Models of Type I Diabetic Neuropathy 
 Rodents have become the principal animal models to study neuropathic changes, 
investigate mechanisms that underlie diabetic neuropathy, and test preclinical disease-
modifying therapies.  Both genetic and drug-induced models exist wh ch mimic a type I 
etiology (Calcutt 2004).  Streptozocin (STZ) is a naturally occurring carcinogen with 
selective pancreatic beta cell toxicity produced by Streptomycetes achromogenes that is 
commonly used to induce experimental diabetes mellitus (Szkudelski 2001).  STZ is 
transported by GLUT2 receptors into beta cells where its potent alkylating properties 
result in toxic DNA damage (Szkudelski 2001).  Shortly after injection, pancreatic insulin 
production is severely reduced to critical levels without affecting glucagon secretion and  
rodents develop elevated plasma glucose levels (Portha, Blondel et al. 1989).  STZ is a 
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conventional method for inducing diabetes mellitus in experimental animals to study 
secondary complications (Rossini, Like et al. 1977; Szkudelski 2001). 
 Existing rodent models of diabetic neuropathy vary in their presentation of 
symptoms and potentially offer insight into alternative pathogenic mechanisms or genetic 
differences that underlie symptom variability.  Behavioral respon es to noxious and non-
noxious stimuli are used to assess the development of diabetic neuropathy in rodents.  
Increased responses to thermal, mechanical, or chemical stimuli are interpreted as either 
hyperalgesia or allodynia, while decreased responses are indicat ve of hypoalgesia or 
insensitivity.   
Several strains of rats with STZ-induced diabetes develop hyperalgesi  to 
mechanical, thermal, and chemical stimuli and tactile and thermal allodynia (Courteix, 
Eschalier et al. 1993).  However, rat models fail to develop fiber loss and neuronal 
degeneration seen in human disease despite prolonged hyperglycemia (Si a and 
Sugimoto 1999; Zochodne 2007).  As well, rats only exhibit the painful aspect of diabetic 
neuropathy while majority of human patients experience sensory loss. 
The STZ-induced diabetes mouse model may better represent human diabetic 
neuropathy because this rodent model shows mild structural changes including myelin 
thinning, electrophysiological changes, and loss of distal innervation that may be similar 
to early pathology seen in human diabetic patients (Calcutt 2004; Zochodne 2007).  Also, 
depending on the strain, either painful or insensate neuropathy can develop in diabetic 
mice.  For instance, diabetic C57BL/6 mice develop progressive mechanical hypoalgesia 
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with reduced intraepidermal nerve density (Christianson, Ryals et al. 2007; Johnson, 
Ryals et al. 2008).  Conversely, diabetic A/J mice develop mechanical allodynia.  Ideally, 
different strains of mice would be used to better understand the dichotomous symptoms 
experienced by human diabetic patients.  This would enable us to study related models to 
investigate potential mechanisms that determine the development of positive versus 
negative symptoms. 
Advanced Glycation Endproducts and Reactive Dicarbonyls 
Introduction 
 As previously discussed, advanced glycation endproducts (AGEs) have been 
shown to have a role in the pathogenesis of diabetic neuropathy.  AGEs are a 
heterogeneous group of molecules that form from the non-enzymatic add tion of sugar 
moieties onto arginine and lysine residues of proteins, free amino groups on lipids, or 
guanine nucleic acids (Peppa, Stavroulakis et al. 2009).  The process of non-enzymatic 
glycation was first described by L.C. Maillard in the early 1900’s and even at that time, 
he speculated it may be an important process in diabetes (Ulrich and Cerami 2001).  It 
has subsequently become apparent that non-enzymatic glycation and AGEs have a role in 
many disease processes such as aging, neurological disorders like Alzheimer’s disease, 
and diabetic complications. 
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Formation of AGEs 
The classical AGE pathway involves the rearrangement of glucose or another 
reducing sugar, such as fructose, galactose, mannose, or ribose, that r acts with a free 
amino group of a protein, which forms a Schiff base (Nass, Bartling et al. 2007) (Figure 
3).  The Schiff base is highly unstable and degrades into the Amadori product or 
fructosamine (Nass, Bartling et al. 2007).  Fructosamine is relativ ly stable, although 
levels tend to fluctuate with glucose concentrations (Huijberts, Schaper et al. 2008).  The 
most well-known example of an Amadori product is hemoglobin A1c (HbA1c), a 
naturally occurring modification to the N-terminal valine amino gr up of the β chain of 
hemoglobin (Ulrich and Cerami 2001).  HbA1c is elevated in diabetic paients and gives 
an indication of glucose levels over the previous 120 days (Koenig, Peterson et al. 1976).  
It is often used to monitor glucose control and has value at predicting risk of 
complications (DCCT 1993; Kankova 2008).  With further rearrangement, oxidation, and 
elimination, fructosamine produces an AGE.  Considerable progress has been made in 
understanding that AGEs form from specific metabolites despite the complexity of the 
glycation process. While intermediate steps in the glycation pathway are reversible, AGE 
formation is irreversible and causes modifications that result in both protease-resistant 
cross-linked and noncross-linked proteins (Ramasamy, Vannucci et al. 2005; Munch, 
Westcott et al. 2010). 
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Reactive Dicarbonyls: Methylglyoxal, Glyoxal, and 3-Deoxyglucose 
 Besides monosaccharides, reactive dicarbonyls or α-oxoaldehydes contribute to 
the production of AGEs.  Reactive dicarbonyls, such as 3-deoxyglucose, glyoxal, and 
methylglyoxal, are highly potent and reactive species that can also modify proteins, 
lipids, and nucleic acids and may contribute more significantly in the glycation process 
than the classical pathway described above.  In fact, reactive dicarbonyls are 20,000-fold 
more reactive than glucose (Turk 2010).  Consequently, reactive dicarbonyls have gained 
increasing acceptance as one of the main mechanisms that drive the production of AGEs, 
produce carbonyl stress, and underlie the development of diabetic complications (Figure 
3).   
 The longstanding view of glycation as a relatively long process that only resulted 
in AGE accumulation on long-lived extracellular proteins was revolutionized with the 
discovery of dicarbonyl metabolites (Huijberts, Schaper et al. 2008).  Methylglyoxal and 
other α-oxoaldehydes form inside cells over a relatively short time period as a byproduct 
of many metabolic pathways (Xue, Rabbani et al. 2011) (Figure 4).  Methylglyoxal is 
formed from spontaneous decomposition of triosephosphates, DHAP and 
glyceraldehyde-3-phosphate, fragmentation of other sugars, and amino acid and ketone 
body degradation (Oya, Hattori et al. 1999; Beisswenger, Howell et a . 2003; Thornalley 
2008).  Glyoxal is also a consequence of degradation of saccharides, but also of lipid 
peroxidation and degradation of glycated proteins (Thornalley 2008).     
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Figure 3: A schematic illustrating the pathways that lead to the production of reactive 
dicarbonyls and AGEs and the mechanisms by which AGEs cause to sens ry neuron 
dysfunction.  The most well characterized pathway that produces AGEs includes 
undergoing rearrangement and reacting with a protein to form a Schiff base.  This is a 
highly unstable molecule then degrades to the Amadori product leading to AGE 
formation.  Reactive dicarbonyls, such as glyoxal and methylglyoxa , are highly reactive 
compounds that also produce AGEs.  Each is formed as a byproduct of many metabolic 
pathways that are all upregulated in diabetes mellitus.  AGEs produce altered sensory 
function via signaling through the RAGE and by modifying intra- and extra-cellular 
proteins.  The glyoxalase system is critical at preventing the formation of AGEs by 
breaking down reactive dicarbonyls. 
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Cellular concentrations of methylglyoxal and glyoxal range from 1-5 µM and 0.1-1 µM, 
respectively (Fleming, Humpert et al. 2010).  The biogenesis of 3-deoxyglucose results 
from the breakdown of fructose-3-phosphate from the polyol pathway (Turk 2010).  It is 
important to note that all of these metabolic processes are enhanced in diabetes mellitus, 
which leads to a significant increase in the production of reactive dicarbonyls and AGEs.
Role in Diabetic Neuropathy 
While only 0.089% of triosephosphates are converted to methylglyoxal, several 
studies have shown levels reactive dicarbonyls are higher in diabetic patients due to 
hyperglycemia (Beisswenger, Drummond et al. 2005; Mirza, Kandhro et al. 2007; Han, 
Randell et al. 2009).  Consequently, reactive dicarbonyl-derived AGEs are elevated in 
plasma and accumulate in tissues prone to secondary complications including the lens, 
retina, kidney, and endothelial vessels of both diabetic humans and rodents (Karachalias, 
Babaei-Jadidi et al. 2003; Ahmed 2005; Ahmed, Babaei-Jadidi et al. 2005; Bohlender, 
Franke et al. 2005; Stitt 2010).  Indeed, the concentration of AGEs in the sciatic nerve of 
diabetic rats is higher than nondiabetic rodents (Karachalias, Babaei-Jadidi et al. 2003; 
Thornalley 2005).  Extensive accumulation of AGEs also occurs in peripheral nerves of 
diabetic patients particularly in the axoplasm of myelinated and unmyelinated neurons, 
Schwann cells, endoneurial and epineurial microvessels, perineurial bas  lamina, and 
perineurium, suggesting AGEs have a role in the development and/or progression of 
neuropathies (Ryle and Donaghy 1995; Sugimoto, Nishizawa et al. 1997; Haslbeck, 
Schleicher et al. 2002; Misur, Zarkovic et al. 2004; Lukic, Humpert et al. 2008).  A recent 
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study investigated skin autofluorescence as a measure of AGE deposition in nondiabetic 
and diabetic subjects with or without neuropathy and found a correlation between 
slowing of SNCV and increased autofluorescence (Meerwaldt, Links et al. 2005).  
Similarly, levels of serum CML or skin autofluorescence were significantly higher in 
type I diabetic patients with microvascular complications, like neuropathy, compared to 
those without complications (Hwang, Shin et al. 2005; Araszkiewicz, Naskret et al. 
2011). 
The pathophysiological consequences of AGE accumulation have been 
investigated in normal aging and in disease states such as Alzheimer’s disease, renal 
failure, inflammation, and some diabetic complications (Ahmed and Thornalley 2007; 
Morcos, Du et al. 2008; Ramasamy, Yan et al. 2008; Chougale, Bhat et al. 2011).  
Several mechanisms are thought to mediate AGE-damage in disease.  In tissues, AGE 
modification of structural and cellular proteins, lipids, and nucleic acids results in 
dysfunction of vital cellular processes with limited proteasomal degradation, increased 
aggregation, and enhanced half-life of glycated proteins (Nass, Bartling et al. 2007; 
Vincent, Perrone et al. 2007).  While a number of proteins, which differ in structure and 
function, are known targets of the glycation process that impairs their structure and 
function, many more likely exist that have yet to be discovered (Mendez, Xie et al. 2010; 
Rabbani and Thornalley 2010).   GAPDH activity was significantly reduced following 
methylglyoxal treatment (Lee, Howell et al. 2005), which causes a compensatory increase 
of the toxic metabolite (Beisswenger, Howell et al. 2003).  Insuli and other key insulin-
signaling molecules, such as insulin receptor substrate 1, were also susceptible to 
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dicarbonyl glycation, which may alter the neurotrophic support for sensory neurons 
(Riboulet-Chavey, Pierron et al. 2006; Schalkwijk, Brouwers et al. 2008).  Methyglyoxal-
modification of extracellular matrix reduced neurite outgrowth of sensory neurons, 
suggesting reactive dicarbonyls could impair the regenerative capacity of DRG neurons 
in diabetic neuropathy.  Methylglyoxal has also been shown to alter the activity and 
expression of the 26S proteasome, as well as other chaperones involved with protein 
control (Schalkwijk, van Bezu et al. 2006; Bento, Marques et al. 2010; Queisser, Yao et 
al. 2010). 
Beyond the effects of protein modification, AGEs also interact with cell surface 
receptors, particularly RAGE, to induce a cascade of intracellular signaling.  Transient 
activation of PI-3K/AKT and MAPK pathways leads to nuclear translocation of NF-κB 
(Vincent, Perrone et al. 2007; Lukic, Humpert et al. 2008).  Continual activation of NF-
κB leads to altered gene expression and upregulation of RAGE creating a positive 
feedback loop that enhances sensory neuron damage (Toth, Martinez et al. 2007).  RAGE 
also stimulates NAD(P)H oxidase, a potent producer of reactive oxygen species (ROS).   
Like glycating agents, excessive ROS alter proteins, lipids, and DNA causing cellular 
damage (Vincent, Perrone et al. 2007).  However, as will be covered later, the source of 
oxidative stress in diabetic neuropathy remains contentious.   
The Glyoxalase System 
 The glyoxalase system, which is composed of the enzymes glyoxalase I (GLO1) 
and glyoxalase II (GLO2), is responsible for detoxifying reactive dicarbonyls (Figure 3).  
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The glyoxalase system was discovered independently by Dakin, Dudley, and Neuberg in 
1913.  At that time, its function of catalyzing the conversion of methylglyoxal to lactate 
was also described (Nass, Bartling et al. 2007; Xue, Rabbani et al. 2011).  Future studies 
revealed that reactive dicarbonyls, like methylglyoxal, react with reduced glutathione 
forming a hemithioacetal (Racker 1951; Mannervik 2008) (Figure 4).  GLO1 converts the 
hemithioacetal to S-2-hydroxyacetylglutathione.  GLO2 then catalyzes this intermediat  
to the corresponding α-hydroxyacid and releases reduced glutathione (Thornalley 2003).   
GLO1 is considered the key enzyme in anti-glycation defense because it is the 
rate-limiting step in the glyoxalase pathway and prevents the accumulation of reactive 
dicarbonyls (Thornalley 1990; Kuhla, Boeck et al. 2006).  GLO1 is highly conserved 
with the enzyme being described in humans, mice, yeast, plants, insects, protozoa, fungi, 
and many bacterial strains (Thornalley 2003).  Due to its critical function, GLO1 has 
been reported to be ubiquitously expressed in the cytosol of all cells (Thornalley 1998; 
Thornalley 2003; Rabbani and Thornalley 2011; Xue, Rabbani et al. 2011) 
While the role GLO1 in diabetic neuropathy has received limited attention, many 
studies related to other secondary complications have developed a clar understanding of 
the protective role of GLO1 in these tissues.  In vitro overexpression of GLO1 in 
endothelial cells under hyperglycemic conditions reduced reactive dicarbonyls 
(Shinohara, Thornalley et al. 1998) and corrected defects in angiogenesis (Ahmed, 
Dobler et al. 2008) and relaxation (Brouwers, Niessen et al. 2010).  Overexpr ssion in the 
lens and retinal capillary pericytes protected against hyperglycemia-induced protein  
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Figure 4: Schematic illustrating of the glyoxalase system.  The glyoxalase system is 
composed of two enzymes, glyoxalase I (GLO1) and glyoxalase II.  Reactive 
dicarbonyls, like methylglyoxal, are effectively detoxified via this metabolic pathway.  
The glyoxalase enzyme pathway catalyzes the conversion of reactive α-oxoaldehydes 
into the corresponding α-hydroxyacids.  In this schematic, methylglyoxal reacts with 
glutathione and is converted to S-D-Lactoylglutathione by GLO1.  This intermediate 
is then broken down into D-lactate by glyoxalase II and reduced glutathione is 
recycled.  Adapted from Thornalley P.J., 2008, Drug Metabol Drug Interact 23(1-
2):125-50. 
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modification (Gangadhariah, Mailankot et al. 2010) and apoptosis (Miller, Smith et al. 
2006), respectively.  Similarly, markers of oxidative damage were reduced in kidneys 
from diabetic transgenic rats overexpressing GLO1 (Brouwers, Niessen et al. 2010). 
Mitochondrial Dysfunction 
Introduction 
 Mitochondrial dysfunction is purported to be one of the mechanisms underlyi g 
the development of diabetic neuropathy.  Among a variety of functions, mitochondria are 
the powerhouse of the cell.  Mitochondria are responsible for producing enery that cells 
harness for all cellular processes such as protein production, cellular transport, and cell 
growth and maintenance.  This is particularly important for neurons given their relatively 
high reliance on energy production due to their increased metabolic deman s (Han, 
Tomizawa et al. 2011).  Consequently, mitochondrial damage and dysfunction have been 
linked to common neurological disorders (Mattson, Gleichmann et al. 2008; Lu 2009).    
Mitochondria, Oxidative Phosphorylation, and ATP Production 
 Mitochondria function in a wide range of biochemical reactions including fatty 
acid oxidation, nutrient production in the citric acid cycle, oxidative phosrylation, and 
ATP production.  Oxidation of NADH and FADH2 from glycolysis, beta oxidation, and 
citric acid cycle releases electrons that are passed through a coordinated series of enzyme 
complexes located in the mitochondrial inner membrane and are finally tr nsferred to 
oxygen (Figure 5).  NADH dehydrogenase or Complex I, cytochrome c reductase or  
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Figure 5: Schematic illustrating the molecular machinery responsible for ene gy 
production in neurons.  The electron transport chain consists of five complexes that 
transfer electrons from complex to complex.  Three complexes, Complexes I, II, and 
IV, create an electrochemical gradient of protons across the inner mitochondrial 
membrane.  ATP synthase or Complex V utilizes this energy gradient to generate 
ATP. Adapted from Brownlee, M., 2005, Diabetes 54(6): 1615-25. 
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Complex III, and cytochrome c oxidase or Complex IV use the redox energy released 
during electron transfer to pump protons from the mitochondrial matrix into the 
intermembrane space which creates an electrochemical gradient across the inner 
mitochondrial membrane (Scheffler 2001).  ATP Synthase or Complex V utilizes the 
electrochemical gradient to produce ATP (Scheffler 2001). 
Reactive Dicarbonyls and Mitochondrial Dysfunction 
While mitochondrial dysfunction has been suggested to be one of the main 
pathogenic mechanisms in diabetic neuropathy, little is known about the nature and 
extent of mitochondrial damage resulting from chronic hyperglycemia.  One mechanism 
by which elevated intracellular glucose clearly alters mitochondrial function is through 
glycation of mitochondrial proteins.  Multiple studies have shown that re ctive 
dicarbonyls form AGEs on mitochondrial oxidative phosphorylation proteins and 
produce changes in mitochondrial respiration, activity of oxidative phosphorylati n 
proteins, and leakage of electrons from these complexes (Rosca, Mustata et al. 2005; 
Morcos, Du et al. 2008; Brouwers, Niessen et al. 2010).  However, some dispute remains 
if mitochondrial dysfunction results in the production of reactive oxygen species and 
oxidative stress in sensory neurons.  A large body of evidence supporting the idea that 
reactive dicarbonyl damage to mitochondria results in oxidative stress comes from 
studies in tissues other than the peripheral nervous system (Rosca, Monnier et al. 2002; 
Rosca, Mustata et al. 2005; Morcos, Du et al. 2008; Rabbani and Thornalley 2008; 
Schlotterer, Kukudov et al. 2009).  While the axons of DRG neurons from diabetic rats 
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exhibited increased ROS and oxidative stress (Zherebitskaya, Akude et al. 2009), 
impaired respiratory function and reduced expression of certain mitochondrial oxidative 
phosphorylation proteins resulted in reduced production of superoxide (Chowdhury, 
Zherebitskaya et al. 2010; Akude, Zherebitskaya et al. 2011). 
Study Significance 
 Diabetic neuropathy is clearly a significant burden on patients a d the healthcare 
system, which will only be growing in the future.  Peripheral sensory neurons are 
damaged by a variety of metabolic insults as a result of hyperglyc mia.  Consequently, 
60-70% of diabetic patients develop diabetic peripheral neuropathy.  However, 30-40% 
of patients remain symptom free.  A genetic basis for the susceptibility or resistance to 
developing diabetic neuropathy complications has been suggested.  Developing an 
understanding of the protective mechanisms that exist in these patients would allow for 
the development of better screening tools and more efficacious therapeutics. 
 Elevated reactive dicarbonyls are a consequence of diabetes-induced 
hyperglycemia.  Reactive dicarbonyls are highly potent producers of AGEs that have 
been shown to have a direct role in the development of diabetic peripheral neuropathy.  
However, the glyoxalase system, particularly the enzyme GLO1, is an mportant pathway 
involved in reducing levels of reactive dicarbonyls by efficiently breaking them down.  
Consequently, GLO1 may have a role in protecting sensory neurons against 
hyperglycemia-induced damage.  Therefore, the goal of this study was to determine the 
relationship between differential GLO1 expression in sensory neurons, the development 
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and/or progression of diabetic neuropathy, and pathological mechanisms which may 
result from hyperglycemia-induced sensory neuron dysfunction with reduced protective 
mechanisms in diabetes mellitus. 
 In the first study, (“Characterization of Glyoxalase I in the Nervous System”), we 
examined the expression and localization of GLO1throughout the peripheral nervous 
system.  We discovered GLO1 abundance is highly variable in various inbred strains of 
mice.  In addition, we showed GLO1 expression to be highly expressed in a subset of 
DRG neurons responsible for pain transmission suggesting that certain populations of 
sensory neurons may be more or less vulnerable reactive dicarbonyls. 
 In the next two studies, we measured the behavioral responses following diabetes 
induction of inbred strains of mice.  In the first, (“Characterization of Glyoxalase I in 
Mouse Models of Painful and Insensate Diabetic Neuropathy”) we inv stigated the 
expression of GLO1 following diabetes induction in mouse models that develop 
dichotomous systems of neuropathy.  C57BL/6 mice with lower levels of GLO1 
expression developed mechanical and thermal insensitivity, while A/J mice with higher 
levels of GLO1 developed mechanical allodynia.  GLO1 expression may lead do an 
imbalance of sensory fiber types that could produce symptoms of neuropathy.  In the next 
study, (“Elevated Glyoxalase I Expression Provides Protection From Diabetes-Induced 
Peripheral Neuropathy”) we used two inbred substrains of BALB/c mice that have related 
genetic backgrounds but express very different amounts of GLO1.  As in the previous 
study, diabetic BALB/cJ mice showed a correlation between reduced GLO1 expression 
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and the development of increased mechanical thresholds, reduced intraepidermal nerve 
fiber density, and impaired expression of mitochondrial oxidative phosphorylati n 
proteins, a known target of reactive dicarbonyls. 
 Finally, in “Mitochondrial Oxidative Phosphorylation Proteins Are Reduc 
Following In Vitro Methylglyoxal Treatment of Sensory Neurons” cultured adult DRG 
neurons were treated with methylglyoxal in vitro to determine if similar reductions of 
oxidative phosphorylation proteins shown in vivo could be caused by elevated reactive 
dicarbonyls.  We found that cultured sensory neurons had reduced expression of electron 
transport chain components following methylglyoxal treatment from certain strains.  This 
study, in part, corroborated that elevated levels of reactive dicarbonyls can result in 
mitochondrial dysfunction. 
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CHAPTER 2 
Characterization of glyoxalase I in the peripheral nervous system 
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1. Abstract 
 The glyoxalase system, particularly the enzyme GLO1protects cells against 
reactive dicarbonyl damage termed carbonyl stress.  Since hyperglycemia leads to an 
accelerated production of α-oxoaldehydes and AGEs, the glyoxalase system has been 
recognized as an important pathway in diabetes mellitus and diabetic complications 
including retinopathy, nephropathy, and microvascular dysfunction.  Previous reports 
have suggested that GLO1 is found in all cells primarily due to its critical function in 
detoxifying methylglyoxal, glyoxal, and 3-deoxyglucose; however, investigation of this 
pathway in the peripheral nervous system has been limited.  Current studies were 
undertaken to characterize GLO1 expression and abundance in the peripheral nervous 
system.  C57BL/6 mice were used to detect the pattern of distribution of GLO1 in the 
nervous system by immunofluorescence.  GLO1immunoreactivity was found throughout 
the nervous system, but selectively in small, unmyelinated peptidergic DRG neurons that 
are involved in pain transmission.  The expression of GLO1, assessed by quantitative 
real-time PCR, was highly variable in the DRG from different inbred mice strain .  Two 
strains showing the largest differences in expression, A/J and C57BL/6 mice, also 
exhibited differences in GLO1 mRNA in the sciatic nerve and brain.  These results 
demonstrate that inbred strains of mice exhibit differential GLO1 expression in both the 
central and peripheral nervous system, but are only heavily expressed in a subpopulation 
of DRG neurons that are responsible for nociception. 
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2. Introduction 
 The peripheral nervous system is composed of primary sensory neurons that vary 
in their anatomical, neurochemical, and, importantly, functional modalities that they 
transmit.  Aβ fibers are heavily myelinated, large diameter neurons that primarily 
transmit information about balance and proprioception from a variety of specializd 
receptors that detect pressure, vibratory, and tactile stimuli.  Aδ fibers are smaller in 
diameter and lightly myelinated, which relay information regarding discriminative touch, 
temperature, and pain.  C-fibers are small, unmyelinated neurons that convey tactil , 
temperature, and noxious information.  Two discrete subpopulations of C-fibers exist, 
peptidergic and nonpeptidergic, which have clear differences in their phenotyp s and 
anatomical locations, suggesting the existence of parallel pain pathways (Br z, Nassar et 
al. 2005).   
These distinct fiber types function to convey normal peripheral sensation, which 
can be altered in disease states.  Therefore, determining differences in th e cell types 
that may render certain populations vulnerable to damage would be beneficial.  The 
glyoxalase system, as discussed in Chapter 1, is a critical enzyme in anti-glyca ion 
defense, which is likely punitive mechanism underlying neurodegeneration in many 
neurological disorders (Munch, Westcott et al. 2010).  Here, we began by investigating 
the expression of GLO1 in the peripheral nervous system.  Our results suggest that high 
GLO1 abundance is restricted to a subpopulation of C-fibers.  Moreover, GLO1 
expression is highly variable in a group of inbred strains of mice.  These findings sug est 
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certain DRG neurons are better able to protect against AGE-induced damage, while 
others are more susceptible to toxic effects of reactive dicarbonyls. 
3. Experimental Procedure 
Animals 
Male C57BL/6 (Charles River, Sulzfeld, Germany), A/J, BALB/cJ, 129P3/J, 
C3H/HeJ, and DBA/2J mice (Jackson, Bar Harbor, Maine) were purchased at 7 weeks, 
one week prior to beginning experiments.  The MrgD mouse line was generated by D. 
Anderson (California Institute of Technology) and maintained as a breeding colony at the 
University of Kansas Medical Center.  Genotypes were confirmed as previously 
described (Johnson, Ryals et al. 2008).  The animals were housed two mice per age in 
12/12-h light/dark cycle under pathogen free conditions.  Mice were given free access to 
standard rodent chow (Harlan Teklad 8,604, 4% kcal derived from fat) and w ter.  All 
animal use was in accordance with NIH guidelines and conformed to principles specified 
by the University of Kansas Medical Center Animal Care and Use Protocol. 
Western Blot 
Brain, lumbar spinal cord, sciatic nerve and DRG were rapidly isolated and 
excised, immediately frozen in liquid nitrogen, and stored at -80oC.  Tissue was 
homogenized for 2 min in 50 µl Cell Extraction Buffer (Invitrogen, Carlsbad, CA) with 
protease inhibitor cocktail (Sigma, St. Louis, MO), 200 mM NaF, and  200 mM Na3VO4.  
The homogenates were incubated on ice for 30 mins before centrifugation at 7000 rpm 
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for 10 mins at 4oC.  Protein concentrations were determined using the Bio-Rad protein 
assay based on the Bradford assay (Bio-Rad, Sydney, NSW, Australia). Samples 
containing 100 µg of protein were separated by electrophoresis through 4-20% SDS-
PAGE gels (125 V, 1.5 h, 4oC) and transferred onto nitrocellulose paper (35 mA, 
overnight, 4oC).  Nitrocellulose membranes were blocked with blocking buffer (3% non-
fat milk and 0.05% Tween-20 in phosphate buffered saline) for 1 hour at room
temperature to block non-specific binding sites.  This was followed by overnight 
incubation with a goat anti-GLO1 primary antibody (R&D Systems, Minneapolis, MN) 
diluted 1:5000 in blocking buffer at 4oC.  The donkey anti-goat IgG-HRP secondary 
antibody (Santa Cruz, Santa Cruz, CA) was used diluted 1:2500 in blocking buffer at RT 
for 1 hour.  The chemiluminescent signal was acquired using Supersignal West Femto 
Maximum Sensitivity Substrate (Pierce, Rockford, IL) and a CCD camera (BioSpectrum 
Imaging System, UVP, Upland, CA). 
Immunohistochemistry 
Unfixed lumbar DRG, sciatic nerve, and spinal cord were dissected, frozen, 
sectioned in 16-20 µm cross-sectional serial sections, and mounted on Superfrost Plus 
slides (Fisher Scientific, Chicago, IL) then stored at -20oC.  After thawing 5 min at room 
temperature, slide-mounted tissue was circled with a Pap Pen (Research Products 
International, Mt. Prospect, Illinois) to create a hydrophobic ring.  Tissue sections were 
then covered with a blocking solution (0.5% porcine gelatin, 1.5% normal donkey serum, 
0.5% Triton-X, Superblock buffer; Pierce, Rockford, IL) for 1 h at room te perature.  
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Primary antibodies were incubated overnight at 4oC.  For GLO1 immunohistochemistry, 
a mouse anti-glyoxalase I primary antibody (1:100; Abcam, Cambridge, MA) and a 
donkey anti-mouse secondary antibody (Alexa 488; 1:2000; Molecular Probes, Eugene, 
OR) were used to label positive cells in the L4/5/6 DRG, sciatic nerve, and spinal cord.  
Primary rabbit anti-neurofilament H (1:2500; Chemicon, Billerica, MA) or rabbit anti-
peripherin (1:1000; Chemicon, Billerica, MA) with donkey anti-rabbit secondary 
antibody (Alexa 555; 1:2000; Molecular Probes, Eugene, OR) were used to label and 
counterstain cell populations in lumbar DRG.  Sections were washed 2 x 5 min with 
PBST followed by incubation for 1 h with fluorochrome-conjugated secondary antibody 
diluted in PBST and Superblock (Pierce, Rockford, IL).  Following three washes with 
PBS, slides were coverslipped and stored at 4oC until viewing.  For quantification, 
positive cells were counted in 3 sections from each lumbar DRG from 3 animals.   
Quantitative Real-Time PCR 
RNA was isolated from sciatic nerve, DRG, and brain using Trizol reagent 
(Ambion, Austin, TX) and RNeasy Mini Kit (Qiagen, Valencia, CA).  The concentration 
and purity were determined using a 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA).  Total RNA (0.63 µg) was synthesized directly into cDNA using the iScript 
cDNA Synthesis Kit (Bio-Rad, Hercules, CA).  qRT-PCR was performed using iScript 
One-Step RT-PCR Kit with SYBR green (Bio-Rad, Hercules, CA).  The primers were as 
follows:  
GAPDH: Forward: 5’-AGGTCGGTGTGAACGGATTTG-3’ 
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Reverse: 5’-TGTAGACCATGTAGTTGAGGTCA-3’  
GLO1: Forward: 5’-GATTTGGTCACATTGGGATTGC-3’ 
Reverse: 5’-TTCTTTCATTTTCCCGTCATCAG 
All reactions were performed in triplicate.  The mRNA levels for GLO1 were normalized 
to GAPDH.  ∆CT values and fold changes were calculated using the Pfaffl analysis 
method (Pfaffl, Horgan et al. 2002). 
4. Results and Figures 
Characterization of GLO1 Expression in the Nervous System 
 To characterize the GLO1-immunoreactivity was detected througout the nervous 
system including both the central and peripheral nervous systems (Figure 1a).  In the 
lumbar spinal cord of 8-week old nondiabetic C57BL/6 mice, GLO1 localized to lamina I 
and outer portions of lamina II of the dorsal horn (Figure 1b), interneuro s (Figure 1b), 
ependymal cells of the central canal (Figure 1e) and ventral ho n motor neurons (Figure 
1f).  In the peripheral nervous system, approximately 36% of L4/L5/L6 DRG neurons (n 
= 1984 out of 5501 neurons) expressed GLO1 at very high levels and these neurons were 
predominately small neurons with diameters ranging from 5-22 µm with an average 
diameter of 13 µm (Figure 1c and 1g).  Consistent with these findings, ~96% of GLO1+ 
neurons expressed peripherin (n = 2115 out of 2198 neurons) (Figure 2e-h), a marker of 
small diameter, unmyelinated neurons with diameters ranging from 27-340 µm2 and an 
average area of 148 µm2.  Accordingly, less than 7% of GLO1+ cells (n = 138 out of 
1994 neurons) expressed heavy chain neurofilament H that labels medium and large  
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Figure 1: GLO1 expression in the nervous system 
 
(a) Representative Western blot showing expression of GLO1 in the brain, lumbar spinal 
cord, DRG, and sciatic nerve of nondiabetic C57BL/6 mice (n = 3).  Immunofluorescence 
staining of the lumbar spinal cord (b), lumbar DRG (c), and sciatic nerve (d) showing 
GLO1 expression and localization.  Arrowheads indicate GLO1-positive interneurons and 
arrows indicate GLO1-positive terminals in the superficial lamina (b).  Enhanced views 
of GLO1-positive ependymal cells of the central canal (e), anterior horn cells (f), neurons 
of the DRG (g), and axons of the sciatic nerve in longitudinal section ounterstained with 
neurofilament H (red) (h) are shown.  Arrowheads indicate a GLO1-positive axon, while 
arrows indicate a neurofilament H-positive axon (h).  Scale bar, 50 µm. 
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diameter, myelinated neurons with areas ranging from 126-1260 µm2 and an average area 
of 552 µm2 (Figure 2a-d).  Correspondingly, GLO1 was expressed in small diameter 
axons in the sciatic nerve (Figure 2d). Moreover, GLO1 appears to be selective to small 
C-fibers based on the somal staining pattern in the DRG, the lack of o-localization of 
GLO1 with neurofilament H large myelinated axons (Figure 1h and 2c), and GLO1 co-
localization with peripherin-positive axons (Figure 2g and 2h).   
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Figure 2:  GLO1 expression in lumbar DRG sensory neurons 
 
Immunofluorescence staining for GLO1 (a and e) with counterstaining for neurofilament 
H (b) and peripherin (f). Merged images (c and g) show GLO1 is localized to small 
neurons in the DRG (n = 3). (d and h) Enhanced views of the merged images are shown.  
Scale bar; 50 µm.   
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MrgD mice have previously been reported to express EGFPf from the Mas-
related G protein-coupled receptor D locus that is expressed exclusively in 
nonpeptidergic DRG neurons innervating the epidermis (Zylka, Rice et al. 2005).  
Because GLO1+ neurons were predominately small, unmyelinated neurons, MrgD mice 
were utilized to determine whether GLO1 was expressed by peptidergic or 
nonpeptidergic sensory neurons.  Only 8% of MrgD-GFP+ neurons (n = 93 out of 1072) 
expressed GLO1, suggesting GLO1 is predominately expressed by peptidergic sensory 
neurons in the L4/L5/L6 DRG (Figure 3). 
Genetic Differences in GLO1 mRNA Expression 
 Quantitative analysis of GLO1 expression in the DRG revealed variable mRNA 
expression in 6 different strains of inbred mice.  C57BL/6, BALB/cJ, and 129P3/J 
showed lowest levels of mRNA expression, while C3H/HeJ and DBA/2J had 
intermediate GLO1 mRNA expression (Figure 4a and 4b).  A/J mice showed the highest 
levels of mRNA expression of the strains examined with a five-fold increase over 
C57BL/6 (Figure 4a and 4b).  These results were also similar in the brain and sciatic 
nerve of A/J mice with 6.7- and 4.2-fold higher levels of GLO1 mRNA compared to 
C57BL/6 mice (Figure 5). 
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Figure 3:  GLO1 expression in peptidergic C-fiber sensory neurons in the DRG. 
Immunofluorescence staining for GLO1 (a) in the lumbar DRG of MrgD mice that 
express GFP from the MrgD locus in nonpeptidergic neurons (b) (n = 3).  Merged image 
(c) shows GLO1 expression primarily in peptidergic C-fibers.  Scale bar; 50 µm. 
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Figure 4: GLO1 mRNA expression is variable in the DRG of inbred strains of mice 
(a) Comparison of GLO1 mRNA expression in the DRG from inbred strains of 
nondiabetic mice (n = 3 for each strain).  Levels are normalized to GAPDH. (b) Fold 
change in GLO1 mRNA expression relative to C57BL/6 mice. * p<0.05 compared to 
C57BL/6. 
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Figure 5: Expression of GLO1 in the nervous system of A/J and C57BL/6 mice 
(a) GLO1 and GAPDH RT-PCR products from the brain, DRG, and sciatic nerve.  (b) 
Comparison of GLO1 mRNA from the brain, DRG, and sciatic nerve of A/J (white bars) 
and C57BL/6  (black bars) mice (n = 3 for each strain).  Levels were normalized to 
GAPDH.  (c) Fold change in GLO1 mRNA expression relative to C57BL/6 (black bars) 
mice in the brain, DRG, and sciatic nerve. * p<0.05 compared to C57BL/6. 
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5. Discussion 
The present study is the first to characterize the expression of GLO1 in the 
peripheral nervous system.  Our results reveal the expression of GLO1 is restricted to 
small, unmyelinated peptidergic neurons in the DRG, which are primarily responsible for 
transmission of noxious or painful sensory information.  This was particul rly interesting 
given the critical function, highly conserved nature, and previous reports of the 
ubiquitous expression of GLO1 (Thornalley 2003).   
 Generally this suggests that different populations of sensory neurons may rely on 
different pathways to detoxify reactive dicarbonyls and prevent AGE formation.  Other 
pathways have been described; however, as mentioned in Chapter 1, the glyoxalase 
system has been reported to be the primary enzyme system that functions to protect cells.  
While other mechanisms are only minor contributors, aldose reductase, betaine aldehyde 
dehydrogenase and 2-oxoaldehye dehydrogenase are also recognized metabolism 
pathways for methylglyoxal (Thornalley 1996; Nemet, Varga-Defterdarovic et al. 2006; 
Turk 2010).  Both betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrog nase 
have remained largely uninvestigated in the nervous system.  However, aldose reductase 
has been reported to be expressed in the peripheral nervous system, particularly abundant 
Schwann cells (Powell, Garrett et al. 1991).  Though GLO1 may have a prominent role in 
reducing reactive dicarbonyls in many cells, populations of sensory neurons other than 
peptidergic neurons may rely on other pathways to detoxify these reactive compounds. 
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On the other hand, if these other detoxifying pathways are not prominent features 
of sensory neurons, this suggests populations of neurons may be vulnerable to diff rent 
types of damage, particularly in diabetes mellitus.  Specifically, nonpeptidergic C-fibers 
and myelinated neurons may experience increased carbonyl stress and accumulation of 
AGEs leading to altered neuronal function.  On the other hand, peptidergic n urons may 
be more protected from the toxic effects of elevated glucose and re ctive dicarbonyls due 
to the expression of GLO1.  This may have significant consequences on the phenotype of 
altered sensation in diabetic neuropathy. 
In this study, GLO1 mRNA expression was shown to be highly variable in the 
DRG from multiple inbred strains of mice.  A previous study using Affymetrix exon arrays 
also reported high genetic variability of GLO1 in the amygdala of a large panel of inbred 
strains of mice (Williams, Lim et al. 2009).  Williams et al. discovered the genomic 
region encoding GLO1 exists as copy number variant (CNV) in mice with certain strains 
undergoing duplications and others having lost the duplicated region due to 
nonhomologous recombination, which could explain expression differences in the DRG 
(Graubert, Cahan et al. 2007; Williams, Lim et al. 2009).   
Interestingly, CNVs have recently been characterized in humans as a substantial 
source of genetic diversity and disease (Choy, Setlur et al. ; Perry, Yang et l. 2008).  In 
fact, a single CNV encompassing GLO1 has been described in humans (Redon, Ishikawa 
et al. 2006).  There are also many intronic and exonic SNPs and SNPs located in 
regulatory 3’ and 5’ UTR regions have been described (Engelen, Ferreira et al. 2009).  In 
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particular, the Ala111Glu SNP has recently been shown to reduce the activity of GLO1, 
which leads to an increase in methylglyoxal levels (Barua, Jenkins et al. 2011) This 
suggests that underlying genetic differences, alterations in regulation, or modifications in 
disease, particularly in diabetes, may influence the expression and activity of GLO1 
(Ranganathan, Ciaccio et al. 1999; Thornalley 2008).  To date, little investigation has 
occurred attempting to define these in humans. 
Finally, the restrictive pattern of GLO1, particularly in MrgD mice, provides 
further evidence for differences in parallel pain pathways.  The two subpopulations of C-
fiber nociceptors have clear biochemical, morphological, anatomical, and developmental 
differences that argue for the existence of two pathways that func ion in normal pain 
sensation (Almeida, Roizenblatt et al. 2004; Braz, Nassar et al. 2005; Zylka 2005; Zylka, 
Rice et al. 2005).  Our results reveal these two subpopulations also have different abilities 
and/or mechanisms by which they manage carbonyl stress.  This has clear implications in 
disease states where pain and sensation are altered as in diabetic neuropathy.  Previous 
work in our laboratory showed peptidergic fibers are lost early in the progression of 
diabetes and this loss correlated with the loss of cutaneous sensitivity in diabetic 
C57BL/6 mice (Johnson, Ryals et al. 2008).  It is plausible to suggest that reduced GLO1 
in peptidergic neurons from this strain may render them more vulnerable to the metabolic 
insults of diabetes mellitus.  
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CHAPTER 3 
 
Characterization of Glyoxalase I in Mouse Models of Painful and Insensate Diabetic 
Neuropathy 
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1. Abstract 
 Diabetic peripheral neuropathy is a common complication of diabetes; however, 
the mechanisms producing positive or negative symptoms are not well understoo .  
Glyoxalase I (GLO1) is an enzyme that detoxifies reactive dicarbonyls that form 
advanced glycation endproducts (AGEs), and GLO1 may affect how sensory eurons 
respond to heightened AGE levels in diabetic neuropathy.  We hypothesize differential 
GLO1 expression levels in sensory neurons may lead to differences in AGE formation 
and modulate the phenotype of diabetic neuropathy.  Diabetic A/J and C57BL/6 mice are 
two mouse strains that express divergent levels of GLO1.  Behavioral assessments were 
conducted on diabetic A/J and C57BL/6 mice to determine mechanical and thermal 
sensitivity.  Strikingly, these two strains display dramatically different behavioral 
responses to mechanical stimuli.  Diabetic A/J mice displayed increased responses to 
mechanical stimuli, characteristic of painful neuropathy.  Conversely, diabetic C57BL/6 
mice developed mechanical and thermal hypoalgesia, which is distinguishing feature of 
insensate neuropathy.  Both strains exhibit loss of epidermal innervation,  feature of 
both painful and painless neuropathy.  Following diabetes induction, diabetic C57BL/6 
showed reduced expression of GLO1. This may have important implications on 
modulation of peripheral sensitivity and lead to the development of different symptoms 
of neuropathy. 
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2. Introduction 
Diabetic peripheral neuropathy is a common and debilitating complication of 
longstanding hyperglycemia as a consequence of diabetes mellitus (Figueroa-Romero, 
Sadidi et al. 2008).  The majority of diabetic patients present with insensate neuropathy 
or negative symptoms, although, estimates have varied widely, suggestin  10-50% of 
diabetic patients have painful neuropathy or positive symptoms (Calcutt nd Backonja 
2007; Tavakoli and Malik 2008; Veves, Backonja et al. 2008).  However, a clear
understanding of the underlying pathological mechanisms that determine which signs and 
symptoms of neuropathy, either positive or negative, arise in certain patients has yet to be 
determined.   
One of the mechanisms linked to neuronal dysfunction in diabetic neuropathy is 
the accumulation of advanced glycation endproducts (AGEs) (Ahmed and Thornalley 
2007; Toth, Martinez et al. 2007).  In clinical studies and diabetic rodent models, AGEs 
accumulate in sites affected by diabetic complications including the kidney, retina, and 
peripheral nerves (Karachalias, Babaei-Jadidi et al. 2003).  In diabetic patients, the 
accumulation of AGEs in the skin precedes clinical neuropathy (Meerwaldt, Links et al. 
2005), correlates with the severity of symptoms (Meerwaldt, Links et al. 2005), and 
predicts the progression of diabetic neuropathy (Genuth, Sun et al. 2005).    
Reactive dicarbonyls or α-oxoaldehydes such as methylglyoxal, glyoxal, and 3-
deoxyglucose have been found to be important precursors of AGEs and contribute in 
their own right to diabetic complications (Ulrich and Cerami 2001; de Arriba, Stuchbury 
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et al. 2007).  As highlighted in Chapter 1, reactive dicarbonyls are formed in many 
metabolic pathways including glycolysis, protein breakdown, lipid peroxidation, and 
degradation of glycated proteins, all of which are heightened in iabetes mellitus 
(Thornalley 2002; Ahmed and Thornalley 2007).  α-oxoaldehydes are up to 20,000-fold 
more reactive than glucose leading to increased carbonyl stress and accelerated 
production of AGEs (Turk 2010).  Therefore, reactive dicarbonyls are thought to have an 
important role in the pathogenesis of diabetic neuropathy. 
The glyoxalase enzyme system, composed of glyoxalase I (GLO1) and glyoxalase 
II, is a key cellular pathway that detoxifies reactive dicarbonyls and limits AGE 
formation.  GLO1 levels and activity can be altered in disease stat s including diabetes 
(Phillips, Mirrlees et al. 1993; Miller, Smith et al. 2006; Fujimoto, Uchida et al. 2008).  
Thus, GLO1 has been investigated in diabetic retinopathy, nephropathy, cardiomyopathy, 
and endothelial dysfunction (Ahmed 2005).  As our previous results have shown, GLO1 
is primarily expressed in small, unmyelinated peptidergic neurons that function to 
transmit noxious information (Jack, Ryals et al. 2011).  And, as discussed in Chapter 2, 
GLO1 exists as a CNV.  Consequently, certain strains that have reduced expression of 
GLO1 in peptidergic neurons may be more vulnerable to developing sensory deficits in 
diabetic neuropathy.  The present study was designed to better und stand the potential 
role of GLO1 in modulating the development of diabetic neuropathy.  Here we 
investigated GLO1 expression in two mouse models of diabetes mellitus that develop 
different characteristics of neuropathy. 
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3. Experimental Procedures 
Animals 
Male C57BL/6 (Charles River, Sulzfeld, Germany) and A/J mice (Jackson, Bar 
Harbor, Maine) were purchased at 7 weeks of age, one week prior to beginning 
experiments. The animals were housed in 12/12-h light/dark cycle under pathogen free 
conditions.  Mice were given free access to standard rodent chow (Harlan Teklad 8,604, 
4% kcal derived from fat) and water.  All animal use was in accordance with NIH 
guidelines and conformed to principles specified by the University of Kansas Medical 
Center Animal Care and Use Protocol. 
Streptozocin-induced diabetes    
Diabetes was induced in 8-week-old male C57BL/6 and A/J mice.  C57BL/6 mice 
were injected with a single intraperitoneal injection of streptozocin (STZ) (180 mg/kg 
body weight; Sigma, St. Louis, MO) dissolved in 10 mmol/l sodium citrate buffer, pH 
4.5.  A/J mice were injected with 85 mg/kg STZ followed by a second injection with 65 
mg/kg STZ 24 hours later.  Controls received sodium citrate buffer alone.  Animals of 
either strain that did not develop hyperglycemia one week after the initial injection were 
re-injected with 85 mg/kg STZ.  Food was removed from all cages for 3 h before and 
after STZ-injection.  Animals did not receive insulin at any time. 
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Glucose measurements  
Animal weight and blood glucose levels (glucose diagnostic reagents, Sigma, St. 
Louis, MO) were measured 1 week after STZ injection and every wek thereafter.  Mice 
were considered diabetic if their nonfasting blood glucose level, measured from tail vein 
sampling for intermediate measures and decapitation pool for the terminal measure, was 
> 12.0 mmol/l at every measurement.   
Mechanical testing  
Mechanical behavioral responses to a Semmes-Weinstein von Frey monofilament 
(1 or 1.4 g) (Stoelting, Wood Dale, Illinois) were assessed at 4, 5, and 6 weeks after STZ 
injection.  Mice underwent a training session on the day prior to the first day of testing.  
Mice were placed in individual clear plastic cages (11 x 5 x 3.5 cm) on a wire mesh 
screen elevated 55 cm above the table and allowed to acclimate for 30 minutes.  The 
combined mean percent withdrawal of three applications to each hindpaw was calculated 
for each animal for each testing session.  The group means were calculated. 
Thermal Testing 
Thermal testing was performed using a thermal analgesiometer (UARDG, La 
Jolla, CA) at 4 weeks after STZ injection.  Mice were placed in individual clear plastic 
compartments on top of a glass surface and allowed to acclimate for 30 min.  A radiant 
heat source (4.0V) was applied to the mid-plantar surface of one hindpaw for  maximum 
of 20 s.  The number of seconds until the animal withdrew its hindpaw was recorded as 
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the latency.  Testing was recorded three times on alternating hindpaws with at least 10 
min separating applications to the same hind paw.  The combined mean withdrawal 
latency of six applications was calculated for each animal.  The group means were 
calculated. 
Hot and cold plate testing was done using a Hot/Cold Plate Analgesia Meter 
(IITC Life Science, Woodland Hills, CA).  Mice were placed in the enclosure over the 
temperature plate.  The initial temperature was set at 25oC for both hot and cold testing.  
The temperature either increased or decreased by 0.1oC/sec until the animal responded.  
A positive response included licking/biting paws, rearing, or jumping and the temperature 
and latency were recorded at that time.  For hot testing, the maximum temperature was 
set at 55oC and for cold testing the minimum temperature was set at 5oC.  The average 
temperature was calculated per group. 
Immunohistochemistry  
Unfixed lumbar DRG were dissected, frozen, sectioned in 16-20 µm cross-
sectional serial sections, and mounted on Superfrost Plus slides (Fisher Scientific, 
Chicago, IL) then stored at -20oC.  After thawing 5 min at room temperature, slide-
mounted tissue was circled with a Pap Pen (Research Products International, Mt. 
Prospect, Illinois) to create a hydrophobic ring.  Tissue sections were then covered with a 
blocking solution (0.5% porcine gelatin, 1.5% normal donkey serum, 0.5% Triton-X, 
Superblock buffer; Pierce, Rockford, IL) for 1 h at room temperature.  Primary antibodies 
were incubated overnight at 4oC.  For GLO1 immunohistochemistry, a mouse anti-
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glyoxalase I primary antibody (1:100; Abcam, Cambridge, MA) and a donkey anti-mouse 
secondary antibody (Alexa 555; 1:2000; Molecular Probes, Eugene, OR) were used to 
label positive cells in the L4/5/6 DRG.  Sections were washed 2 x 5 min with PBST 
followed by incubation for 1 h with fluorochrome-conjugated secondary antibody diluted 
in PBST and Superblock (Pierce, Rockford, IL).  Following three washes with PBS, 
slides were coverslipped and stored at 4oC until viewing. 
Quantitative Real-Time PCR  
 Total RNA was isolated from DRG of diabetic and nondiabetic C57BL/6 mice 
using Trizol reagent (Ambion, Austin, TX) and RNeasy Mini Kit (Qiagen, Valencia, 
CA).  The concentration and purity were determined using a 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA).  Total RNA (0.63 µg) was synthesized directly into 
cDNA using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA).   qRT-PCR was 
performed using iScript One-Step RT-PCR Kit with SYBR green (Bio-Rad, Hercules, 
CA).  The primers were as follows:  
 
GAPDH: Forward: 5’-AGGTCGGTGTGAACGGATTTG-3’  
Reverse: 5’-TGTAGACCATGTAGTTGAGGTCA-3’  
GLO1: Forward: 5’-GATTTGGTCACATTGGGATTGC-3’ 
Reverse: 5’-TTCTTTCATTTTCCCGTCATCAG 
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All reactions were performed in triplicate.  ∆CT values and fold changes were calculated 
using the Pfaffl analysis method (Pfaffl, Horgan et al. 2002).  The mRNA levels for 
GLO1 were normalized to GAPDH. 
Western blot 
DRG were rapidly isolated, frozen in liquid nitrogen, and stored at -80oC.  Tissue 
was homogenized for 2 min in 50 µl Cell Extraction Buffer (Invitrogen, Carlsbad, CA) 
with protease inhibitor cocktail (Sigma, St. Louis, MO), 200 mM NaF, nd 200 mM 
Na3VO4.  The homogenates were incubated on ice for 30 mins before centrifugation at 
7000 rpm for 10 mins at 4oC.  Protein concentrations were determined using the Bio-Rad 
protein assay based on the Bradford assay (Bio-Rad, Sydney, NSW, Australia). 
Samples containing 100 µg of protein were separated by electrophoresis through 
4-20% SDS-PAGE gels (125 V, 1.5 h, 4oC) and transferred onto nitrocellulose paper (35 
mA, overnight, 4oC).  Nitrocellulose membranes were blocked with blocking buffer (3%
non-fat milk and 0.05% Tween-20 in phosphate buffered saline) for 1 hour at room 
temperature to block non-specific binding sites, followed by overnight incubation with a 
goat anti-GLO1 primary antibody (R&D Systems, Minneapolis, MN) diluted 1:5000 in 
blocking buffer at 4oC.  The donkey anti-goat IgG-HRP secondary antibody (Santa Cruz, 
Santa Cruz, CA) was used diluted 1:2500 in blocking buffer at RT for 1 hour.   
Nitrocellulose membranes were stripped using Restore Plus Western Blot 
Stripping Buffer (Pierce, Rockford, IL), followed by 1-hour incubation with an actin 
primary antibody (Millipore, Billerica, MA) diluted 1:100,000 in blocking buffer at RT.  
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The donkey anti-mouse IgG-HRP secondary antibody (Santa Cruz, Santa Cruz, CA) was 
used diluted 1:2500 in blocking buffer at RT for 1 hour.  The chemiluminesce t signal 
was acquired using Supersignal West Femto Maximum Sensitivity Substrate (Pierce, 
Rockford, IL) and a CCD camera (BioSpectrum Imaging System, UVP, Upland, CA).  
NIH ImageJ software was used to measure and quantify densitometry readings. 
Intraepidermal Nerve Fiber Density 
Cutaneous innervation of the footpad was assessed in nondiabetic and diabetic 
mice after seven weeks of diabetes.  The right footpad skin was harvested from mice at 
the time of sacrifice and immersion fixed in Zamboni’s fixative (4% paraformaldehyde, 
14% saturated picric acid, 0.1 M phosphate buffered saline; pH 7.4) for 1 h ur on ice.  
Footpads were washed in PBS twice and placed in PBS overnight at 4oC.  Footpads were 
then cryoprotected in 30% sucrose overnight at 4oC.  30 µm serial sections were cut and 
placed on Superfrost Plus microscope slides (Fischer, Chicago, IL).  
Immunohistochemistry was performed as previous described (Christianson, Ryals et al. 
2007; Johnson, Ryals et al. 2008).  Small cutaneous, PGP9.5+ fibers that crossed the 
dermal-epidermal junction were quantified in three areas from three tissue sections from 
each footpad.  The length of the dermal-epidermal junction was measured and 
intraepidermal nerve fiber density (IENFD) was expressed as the number of fibers per 
millimeter. 
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Statistics 
Data are expressed as mean ± SEM.  Differences were analyzed using Student’s 
T-test or ANOVA followed by Bonferroni’s test, as appropriate.  Significance was 
defined as p ≤ 0.05. 
4. Results and Figures 
STZ Induced Diabetes 
Following STZ injection, C57BL/6 and A/J mice developed significantly higher 
blood glucose that persisted throughout the course of the 6-week study (Figure 1a).  Both 
strains showed similar blood glucose levels after diabetes induction (F gure 1a).  Diabetic 
A/J mice had significantly lower body weights than nondiabetic mice.  Nondiabetic A/J 
mice gained 2.1 ± 0.7 g on average, while diabetic A/J mice lost 4.6 ± 0 5 g on average 
(Figure 1b).  Diabetic C57BL/6 also had significantly lower body weights compared to 
nondiabetic C57BL/6 mice and failed to gain weight over the course of the study (Figure 
1b).  Both diabetic C57BL/6 and A/J mice also displayed other characteristic symptoms 
of type I diabetes, including polydipsia and polyuria. 
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Figure 1:  Blood glucose and weights of diabetic A/J and C57BL/6 mice 
(a) Blood glucose and (b) weights of C57BL/6 (n = 5 nondiabetic, closed circles, 9 
diabetic, open circles) and A/J (n = 5 nondiabetic, closed triangles, 9 diabetic, open 
triangles) mice.  Circles represent Blood glucose is expressed in mmol/l and weight is 
expressed in grams.  Data represents means ± standard error of the mean.  # p<0.05 vs. 
C57BL/6 nondiabetic.  #### p<0.0001 vs. C57BL/6 nondiabetic.  **** p<0.0001 vs. A/J 
nondiabetic 
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Behavioral Sensitivity to Mechanical Stimuli 
Assessment of baseline behavioral responses to a 1.4 g Von Frey mechanical 
stimulus revealed that C57BL/6 and A/J mice displayed different mechanical sensitivity 
(Figure 2a).  A/J mice displayed a higher average percent withdrawal following 6 
applications of Von Frey monofilaments and, therefore, were more sensitiv  to force 
applied to the hindpaw than C57BL/6 (Figure 2a).  Consequently, a smaller fil ment, 1.0 
g, was chosen to test the mechanical sensitivity of A/J mice in order to detect behavioral 
changes following diabetes induction. 
Mechanical sensitivity of the hindpaw was tested at 4, 5, and 6 weeks after STZ 
injection. Consistent with this strain and model, diabetic C57BL/6 mice showed reduced 
responses to a 1.4-g von Frey monofilament (Figure 2c) (Christianson, Ryals et al. 2003; 
Johnson, Ryals et al. 2008).  After four weeks of diabetes, diabetic C57BL/6 mice 
displayed a withdrawal response to mechanical stimulation an average of 41.2% ± 5.32, 
while nondiabetic mice responded 64.4% ± 11.7 of the time.  This mechanical 
insensitivity persisted and worsened with progression of the disease with diabetic mice 
withdrawing 23.2% ± 2.97 at 6 weeks post-STZ (Figure 6c; 4- vs. 6-week post-STZ).   
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Figure 2: Behavioral responses of mice to mechanical stimulation of the hind paw.   
(a) Baseline behavioral measurements of nondiabetic A/J (n = 15) and C57BL/6 (n = 12) 
mice using a 1.4 g monofilament.  The percent paw withdrawal is the percentage of 
responses following six repeated applications of von Frey monofilaments.  Either a 1.0 g 
or 1.4 g were applied to the hindpaws of A/J (b, n = 4 nondiabetic, closed circles, 4 
diabetic, open circles) and C57BL/6 (c, n = 7 nondiabetic, closed triangles, 34 diabetic, 
open triangles) mice, respectively.  Data represents means ± standard error of the mean.  
* p<0.05 vs. nondiabetic.  ** p<0.01 vs. nondiabetic. 
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Conversely, as early as 1 week following STZ injection, diabetic A/J mice 
displayed increased responses to a 1-g von Frey monofilament (data not shown).  
Mechanical allodynia was present at 4, 5, and 6 weeks following STZ injection with 
diabetic A/J mice responding nearly 75% of the time (Figure 2b).  Thus, diabetic 
C57BL/6 mice develop increased mechanical thresholds and severe mchanical 
insensitivity, whereas diabetic A/J mice developed reduced mechanical thresholds and 
mechanical allodynia after 4 weeks of diabetes.   
Behavioral Sensitivity to Thermal Stimuli 
 Thermal sensitivity of the hindpaw was tested with a thermal an gesiometer at 4 
weeks after STZ injection.  Diabetic C57BL/6 mice exhibited increased latency to the 
time of withdrawal from a radiant heat source applied to the hindpaw (Figure 3a).  
However, diabetic A/J mice had similar latencies to nondiabetic mice, 13.1 s ± 0.8s vs. 
14.4 s ± 1.4 s, respectively (Figure 3b).   
 Because thermal latencies were not different, A/J mice underwent hot and cold 
plate testing at 5 and 6 weeks following STZ injection to determine if either of the 
thermal thresholds was different at later time points. Diabetic A/J mice did not display 
altered sensitivity to either hot (Figure 4a and 4b) or cold (Figure 4c and 4d) 
temperatures.  Diabetic A/J mice showed positive responses to hea at an average 
temperature of 46.6 oC ± 1.2 at week 5 and 45.9 oC ± 0.6 at week 6 following diabetes 
induction, while nondiabetic A/J mice displayed responses at average temperatures of 
46.5 oC ± 0.7 and 46.8 oC ± 0.3 (Figure 4a and 4b).  Again, cold thresholds were not  
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Figure 3: Thermal testing of nondiabetic and diabetic C57BL/6 and A/J mice 4 
weeks after diabetes induction 
(a) Thermal testing of nondiabetic and diabetic C57BL/6 (n = 6-7) and (b) A/J (n = 6-7) 
mice using a radiant light source applied to the hindpaw.  The latency is the length of 
time until the mouse displayed a withdrawal behavior such as retracting or licking the 
hindpaw.  Data represents means ± standard error of the mean.  * p<0.05 vs. nondiabetic 
C57BL/6. 
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Figure 4: Hot and cold plate testing of nondiabetic and diabetic A/J mice at five and 
six weeks after STZ injection 
(Top) Heat thresholds of nondiabetic and diabetic A/J (n = 6-7) at (a) 5 weeks and (b) 6 
weeks after diabetes induction. (Bottom) Cold thresholds of nondiabetic and di betic A/J 
(n = 6-7) at (c) 5 weeks and (d) 6 weeks after STZ injection.  The threshold temperature 
was recorded when the animal displayed withdrawal activity such as biting or licking the 
hindpaw, jumping, or rearing.  Data represents means ± standard error of the mean. 
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different at either of the two time points tested with nondiabetic A/J mice responding at 
average temperatures of 11.4 oC ± 0.6 and 9.2 oC ± 1.4 and diabetic A/J mice responding 
at average temperatures of 12.2 oC ± 0.8 and 11.0 oC ± 2.0 (Figure 4c and 4d).  Latencies 
to withdrawal were also not significantly different between groups at either time tested.  
Intraepidermal Nerve Fiber Density 
 Although nondiabetic A/J mice had more than twice the number of fibers in the 
epidermis than nondiabetic C57BL/6, diabetic mice from both strains displayed changes 
in fiber density following diabetes induction.  After 7 weeks of diabetes, both diabetic 
A/J and C57BL/6 mice displayed reduced epidermal innervation of the hindpaw (Figure 
5).  Diabetic C57BL/6 mice showed a 44% loss in epidermal axons, while diabetic A/J 
mice underwent a 30% reduction in fiber density (Figure 5).   
GLO1 Expression in Diabetes 
After 6 weeks of diabetes, GLO1 protein levels in the DRG of diabetic A/J mice 
remained similar to nondiabetic mice (Figure 6a and 6b).  In contrast, diabetic C57BL/6 
mice showed a 59.6% reduction in GLO1 expression in the lumbar DRG (Figure 6a and 
6c).  There was no difference in GLO1 mRNA levels of diabetic C57BL/6 mice 
compared to the nondiabetic counterparts (Figure 6d). 
The pattern of GLO1 expression in the DRG did not change following diabetes 
induction. Small-diameter neurons predominately expressed GLO1 in both nondiabetic 
and diabetic mice (Figure 7a-d).  The percentage of GLO1+ neurons from both diabetic  
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Figure 5:  Effect of diabetes on intraepidermal nerve fiber density in diabetic A/J 
and C57BL/6 mice 
Representative photomicrographs of skin from the right footpad of (a) nondiabetic 
C57BL/6, (b) diabetic C57BL/6, (c) nondiabetic A/J, and (d) diabetic A/J mice.  Diabetic 
mice show a reduction in PGP9.5-positive cutaneous nerve fibers in the skin.  Scale bar = 
50 µm.  (e)  Quantification of IENFD of nondiabetic (black bars) and diabetic (white 
bars) C57BL/6 and A/J mice.  Data plotted as means ± SEM. *p < 0.05 vs. nondiabetic.  
Scale bar; 50 µm. 
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Figure 6:  Effect of diabetes on levels of GLO1 in the DRG of A/J and C57BL/6 
mice.  
(a) Representative Western blots from nondiabetic and diabetic A/J (left) and C57BL/6 
(right) mice are shown for GLO1 and actin.  Quantification of protein band intensities for 
A/J mice (b, n = 3 nondiabetic, 3 diabetic) and C57BL/6 mice (c, n = 3 nondiabetic, 3 
diabetic).  Band intensities are shown as normalized means ± standard error of the mean.  
(d) Comparison of GLO1 mRNA expression in the DRG from nondiabetic and di betic 
C57BL/6 mice after six weeks of diabetes (n = 3).  **p<0.01 compared to nondiabetic. 
 
 
 
 
 
 
82 
 
Figure 6
 
83 
 
strains was similar to their nondiabetic counterparts, 30 ± 2% for nondiabetic C57BL/6 (n 
= 663 out of 2194) vs. 28 ± 2% for diabetic C57BL/6 (n = 756 out of 2660) and 29 ± 2% 
for nondiabetic A/J (n = 597out of 2032) vs. 26 ± 1% for diabetic A/J (n = 468 out of 
1795) (Figure 7e).  Similarly, the number of GLO1+ neurons from both diabetic 
C57BL/5 and A/J mice was comparable (Figure 7e).
5. Discussion 
 Chronic hyperglycemia is the main driving force of the development and 
progression of diabetic neuropathy.  Elevated intra- and extra-cellular glucose 
concentrations lead to accelerated production of AGEs.  AGEs alter the function of many 
proteins including tubulin, mitochondrial electron transport chain proteins, insulin, and 
neuronal extracellular matrix proteins (Mendez, Xie et al. ; Williams, Howarth et al. 
1982; Rabbani and Thornalley 2008; Schalkwijk, Brouwers et al. 2008; Thornalley 2008; 
Duran-Jimenez, Dobler et al. 2009). 
 AGEs are elevated in peripheral nerves and skin of both diabetic patients and 
rodents (Chabroux, Canoui-Poitrine et al. ; Karachalias, Babaei-Jadidi et al. 2003; 
Meerwaldt, Links et al. 2005; Yu, Thorpe et al. 2006), and elevated lev ls have also been 
measured in plasma of type I diabetic patients without complications, suggesting AGEs 
may have a role in the development and/or progression of diabetic neuropathy (H n, 
Randell et al. 2009).  GLO1, a key enzyme in anti-glycation defense, is critical to 
preventing this accumulation of AGEs and limiting their toxic effects by breaking down 
the highly reactive precursors, α-oxoaldehydes. 
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Figure 7:  The pattern of GLO1 expression in the DRG following 6 weeks of 
diabetes.   
Immunofluorescence staining for GLO1 in the DRG of A/J nondiabetic (a, n = 3) and 
diabetic (b, n = 3) and C57BL/6 nondiabetic (c, n = 3) and diabetic (d, n = 3) mice.  Scale 
bars; 50 µm.  (e) Quantification of the percentage of GLO1 positive neurons of total 
neurons in the DRG.  Black bars represent nondiabetic mice and white bars represent 
diabetic mice.  Data represents means ± standard error of the mean. 
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 In this study, diabetic mice expressing different levels of GLO1 showed variable 
responses to mechanical stimuli.  Previous studies have also suggested a link between 
mechanical and thermal sensation, GLO1, and AGEs.  Both Bierhaus et l. and Toth et 
al. showed RAGE has a role in sensory neuron dysfunction in diabetes (Bi rhaus, 
Haslbeck et al. 2004; Toth, Rong et al. 2008).  Diabetic RAGE-/- mice were protected 
from pathological, physiological, and behavior signs of DN (Bierhaus, Halbeck et al. 
2004; Toth, Martinez et al. 2007; Toth, Rong et al. 2008). Mechanical sensitivity is 
mediated by both unmyelinated and myelinated sensory neurons that respond to a range 
of sensory stimulus modalities.  Indeed, most C-fibers also respond to mechanical 
sensitivity (Rau, McIlwrath et al. 2009).  Thus, afferent information encoding mechanical 
information likely converges in the spinal cord to convey complex mechano-sensory 
information.  Thus, it is plausible to suggest that a balance between fiber types is required 
to convey appropriate sensory information from the periphery.  The ability of specific 
neuronal populations to be more susceptible to and/or protect against hyperglycemia-
induced damage, which occurs in diabetes, may alter this balance leading to abnormal 
peripheral nociceptive input and produce different signs and symptoms of neuropathy.  
Based on our findings, it is plausible hypothesize that an imbalance of fiber type 
input may underlie the development of positive or negative mechanical sensitivity. In the 
setting of high GLO1 expression, as in A/J mice, peptidergic neurons may be protected 
from extensive damage by reactive dicarbonyls and retain the ability to transmit noxious 
sensory information.  However, A-fiber and nonpeptidergic sensory neurons have no 
detectable expression of GLO1 and may be more vulnerable to direct damage by reactive 
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dicarbonyl that leads to neuronal dysfunction in these fibers. This is supported by studies 
that suggest that a range of sensory afferents likely contribute to overall pain sensation, 
including both A and C-fibers (Shields, Cavanaugh et al. 2010).  Therefor , despite 
protection from GLO1, it is possible that peptidergic C-fiber functio  may be affected by 
damage to other fibers which could lead to hyperexcitability and peripheral sensitization 
(Wu, Ringkamp et al. 2002; Ringkamp and Meyer 2005; Meyer and Ringkamp 2008).   
Conversely, in the setting of low GLO1 expression, as in C57BL/6 mice, 
peptidergic neurons may accumulate reactive dicarbonyl-derived AGEs and experience 
physiological dysfunction similar to other fibers.  Thus, peptidergic C-fiber mechano-
thresholds may be increased due to intrinsic dysfunction stemming from reduced GLO1 
expression and accumulation of reactive dicarbonyls.  Previous studies in C57BL/6 mice 
have demonstrated that a reduction in peptidergic C-fibers following diabetes induction 
mirrored the loss of both mechanical and thermal sensitivity (Johnson, Ryals et al. 2008).  
Because this population of sensory neurons expresses GLO1 at significantly lower levels 
than other strains, particularly A/J mice, elevated intracellular glucose and reactive 
dicarbonyls could overwhelm the protective enzyme system and cause sensory 
dysfunction.   
Nonpeptidergic fibers are by far the most prevalent C-fiber subpopulation 
innervating the epidermis (Lindfors, Voikar et al. 2006) with only 25-40% of the total 
fiber population classified as peptidergic (Zylka, Rice et al. 2005; Johnson, Ryals et al. 
2008).  Interestingly, the loss of cutaneous innervation is a hallmark of both painful and 
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painless neuropathy (Tavee and Zhou 2009).  However, precise fiber-type changes in the 
skin have not been characterized as they have in rodents.  However, overt fiber loss 
quantified in both diabetic C57BL/6 and A/J mice are likely nonpeptidergic fibers and 
peptidergic loss, in the case of C57BL/6, is masked by overall total innervation (Johnson, 
Ryals et al. 2008).  It remains to be determined what percentage of peptidergic fibers, if 
any, is lost in A/J mice. 
Although the present study does not directly address the mechanisms causing 
either positive or negative mechanical sensitivity associated with diabetic neuropathy, 
this issue is clearly important and relevant to humans with diabetic n uropathy.  Sensory 
loss, including chronic numbness and insensitivity to pain or touch, develops in the 
majority of affected human patients. Painful symptoms, including tactile allodynia, are 
reported in approximately 30% of patients with DN, oftentimes present early in the 
disease progression, and have a slightly higher prevalence in type 2 diabetes (Sorensen, 
Molyneaux et al. 2002; Quattrini and Tesfaye 2003).  This dichotomy in positive vs. 
negative symptoms is reflected in animal models of diabetic neuropathy, with some 
resembling the painful, and others the painless aspects of diabetic n uropathy 
(Christianson, Ryals et al. 2003; Walwyn, Matsuka et al. 2006; Calcutt and Backonja 
2007).  Our current findings in C57BL/6 and A/J mice are consistent with this feature and 
may provide approaches address how genetic differences, including altered GLO1 
expression, may help shape the phenotype of diabetic neuropathy in diabetic patients.  
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Finally, our results revealed that GLO1 levels are reduced by diabetes in C57BL/6 
mice, which could also play a role in determining the phenotype of the DN.  Reductions 
in GLO1 in diabetic C57BL/6 mice could occur through increased proteosomal 
degradation, particularly if GLO1 itself is modified by methylgl oxal, or by RAGE-
mediated reduction in GLO1 (Thornalley 2008).  Both in vivo and in vitro overexpression 
of GLO1 has been shown to dramatically reduce the levels of reactiv  dicarbonyls and 
AGEs (Shinohara, Thornalley et al. 1998; Ahmed, Dobler et al. 2008; Morcos, Du et al. 
2008).  However, it remains to be seen if physiological overexpression is robust enough 
to produce similar reductions.  Given the restricted expression pattern of GLO1 in the 
DRG and behavioral differences following induction of diabetes, our findings suggest 
that genetic variability in GLO1 could be a modifier of the spectrum of DN sympto s. 
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Elevated Glyoxalase I Expression Provides Protection From Diabetes-Induced 
Peripheral Neuropathy 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
1. Abstract 
Diabetic neuropathy is a common complication of diabetes mellitus wi h over half 
of all patients developing neuropathy symptoms due to sensory nerve damage.  Di b tes-
induced hyperglycemia leads to the accelerated production of advance glycation end 
products (AGEs) that alter proteins, thereby leading to neuronal dysfunction.  The 
glyoxalase enzyme system, specifically glyoxalase I (GLO1), is responsible for 
detoxifying precursors of AGEs, such as methylglyoxal and other reactive dicarbonyls.  
The purpose of our studies was to determine if expression differences of GLO1 play a 
role in the development of diabetic sensory neuropathy.  BALB/cJ mice naturally express 
low levels of GLO1, while BALB/cByJ express approximately 10-fold higher levels on a 
similar genetic background due to increased copy numbers of GLO1.  Five weeks 
following STZ injection, diabetic BALB/cJ mice developed a 68% increase in 
mechanical thresholds, characteristic of insensate neuropathy or loss of mechanical 
sensitivity.  This behavior change correlated with a 38% reduction in i traepidermal 
nerve fiber density (IENFD).  Diabetic BALB/cJ mice also had reduced expression of 
mitochondrial oxidative phosphorylation proteins in Complex I and V by 83% and 47%, 
respectively.  Conversely, diabetic BALB/cByJ mice did not develop signs of 
neuropathy, changes in IENFD, or alterations in mitochondrial protein expression.  
Reduced expression of GLO1 paired with diabetes-induced hyperglycemia may lead to 
neuronal mitochondrial damage and symptoms of diabetic neuropathy. Therefore, AGEs, 
the glyoxalase system, and mitochondrial dysfunction may play a role in the development 
and modulation of diabetic peripheral neuropathy. 
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2. Introduction 
 As covered in Chapter 1, diabetic neuropathy is a secondary consequence of 
longstanding diabetes mellitus.  Sensory neurons appear particularly vulnerable to 
elevated glucose and damage in diabetes mellitus (Zochodne, Ramji et al. 2008).  
Consequently, 50-70% of patients develop diabetic neuropathy signs and symptoms 
throughout the course of the disease (Centers for Disease Control and Prevention 2011).  
Moreover, diabetic neuropathy remains a growing problem in the United States and 
throughout the world with only limited symptomatic treatments (Edwars, Vincent et al. 
2008).   
 Although the pathogenesis of diabetic neuropathy is likely multifactorial, one 
mechanism leading to sensory neuron damage and dysfunction is the accumulation of a 
heterogeneous group of reactive sugars known as advanced glycation endproducts 
(AGEs) (Ahmed 2005; Brownlee 2005).  As discussed in Chapter 1, AGEs can form via a 
number of pathways inside and outside the neuron.  In particular, reactive dicarbonyls, a 
potent producer of AGEs, are formed as a normal byproduct of glycolysis, lipid 
peroxidation, and degradation of glycated proteins (Ahmed and Thornalley 2007; 
Thornalley 2008).  Each of these processes is enhanced in diabetes mellitus leading to an 
increased formation of toxic reactive dicarbonyls.  Once formed, reactiv  dicarbonyls 
react with proteins, lipids, or nucleic acids forming AGEs and cause neuronal dysfunction 
(Thornalley 2008). 
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 The glyoxalase system functions to detoxify reactive dicarbonyls before they react 
with cellular components and form AGEs (Rabbani and Thornalley 2011).  The 
glyoxalase system is composed of two enzymes, glyoxalase I (GLO1) and glyoxalase II, 
that detoxify reactive dicarbonyls by converting them to lactic acid, thereby preventing 
the formation of AGEs (Thornalley 2003).  As our previous results have shown in 
Chapter 2, GLO1 is primarily expressed in small, unmyelinated peptidergic neurons, a 
subset of DRG neurons that are responsible for pain transmission in the peripheral 
nervous system (Jack, Ryals et al. 2011).  While GLO1 has been investigat d in other 
diabetic complications, its role in diabetic neuropathy has remained largely 
uninvestigated.  
GLO1 exists as a copy number variant (CNV) in many inbred strain  mice 
(Williams, Lim et al. 2009).  In particular, BALB/cByJ mice have multiple copies, while 
BALB/cJ mice have a single copy (Williams, Lim et al. 2009).  BALB/cByJ and 
BALB/cJ mice originated from the same parental strain and were s parated in the 1930s 
(Bailey 1978).  Despite 80 years of segregated inbreeding, these two strains remain 
isogenic at all typed SNPs (Williams, Lim et al. 2009; Velez, Sokoloff et al. 2010). 
However, BALB/cJ have lost multiple copies of the region encompassing GLO1 
(Williams, Lim et al. 2009).  Thus, BALB/cByJ and BALB/cJ mice express variable 
levels of GLO1 on similar genetic backgrounds.  
In Chapter 3, we investigated behavioral deficits in two strains that express 
different levels of GLO1 and develop diverse sensory deficits following diabetes 
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induction.  However, these two strains have different genetic backgrounds.  
Consequently, we chose to use two substrains of BALB/c mice to determine diabetes-
induced behavior deficits in mouse models that vary in their GLO1 expression. 
Given the clear evidence showing GLO1 has a role in protecting against 
hyperglycemia-induced diabetic complications including nephropathy and endothelial 
dysfunction, GLO1 may also have a role in protecting sensory neurons f m the 
damaging effects of diabetes mellitus (Wautier and Schmidt 2004; Ahmed, Dobler et al. 
2008).  In this study, we took advantage of the natural genetic variation n substrains of 
BALB/c mice to investigate sensory damage in diabetic neuropathy in strains expressing 
different amounts of GLO1.  Our results suggest that higher expression of GLO1 protects 
against neuropathy-related behavior changes and sensory neuron damage associated with 
elevated reactive dicarbonyls. 
3. Experimental Procedures 
Animals 
Male BALB/cJ and BALB/cByJ mice (Jackson, Bar Harbor, ME) were purchased 
at 7 weeks, one week prior to the onset of experimental testing.  BALB/cJ mice were 
housed one mouse per cage, while BALB/cByJ mice were housed two per cage in 12/12-
h light/dark cycle under pathogen free conditions.  Mice were given fre access to 
standard rodent chow (Harlan Teklad 8,604, 4% kcal derived from fat) and wter.  All 
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animal use was in accordance with NIH guidelines and conformed to principles specified 
by the University of Kansas Medical Center Animal Care and Use Protocol. 
Diabetes Induction 
Diabetes was induced in 8-week-old male BALB/cJ and BALB/cByJ mice.  
BALB/cJ and BALB/cByJ mice were injected with a single intraperitoneal injection of 
streptozocin (STZ) (260 mg/kg and 200 mg/kg body weight, respectively; Sigma, St. 
Louis, MO) dissolved in 10 mmol/L sodium citrate buffer, pH 4.5.  Controls received 
sodium citrate buffer alone.  Animals of either strain that did not develop hyperglycemia 
three days after the initial injection were re-injected with STZ (200 mg/kg body weight).  
Food was removed from all cages for 3 h before and after STZ injection.  Animals did not 
receive insulin at any point in the study. 
Glucose Measurements 
Animal weights and blood glucose levels (glucose diagnostic reagents, Sigma, St. 
Louis, MO) were measured three days and one week after STZ injectio .  Both were then 
measured every week thereafter from tail vein sampling and decapitation blood pool for 
terminal measurements.  Mice were considered diabetic if theirfasting blood glucose 
level is greater than 200 mg/dl at every measurement. 
Behavior Testing 
Mice underwent training sessions on the four days prior to behavioral testing.  
Mice were placed into individual clear plastic cages on a wire mesh screen elevated 55 
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cm above the table.  Mice were allowed to acclimate in their cages to the behavior room 
for 30 minutes and on the mesh grid for 15-45 minutes on the table during the training 
sessions, depending on the training day.  Before each behavioral testing session, mice 
were allowed to acclimate to the behavior room in their cages for 30 minutes and to the 
wire mesh grid for 15 minutes.  The up-down method was used to test mechanical 
sensitivity (Dixon 1980).  Briefly, a set of standard von Frey monofilaments (0.02, 0.07, 
0.16, 0.4, 1.0, 2.0, 6.0, and 10.0 g) were used.  Beginning with the 0.4 g monofilament, 
mice received a single application to the right hindpaw.  Depending on the response of 
the mouse to the previous application, the next smaller filament was used if there was 
negative response or the next larger gram filament was used if there was a positive 
response.  This was repeated on each mouse until there was a change from either a 
positive response to negative response or vice versa.  Four trials after the change were 
then conducted with 5 min intervals between applications.  A positive response was 
considered a brisk withdrawal of the paw to which the force was applied.  Five negative 
responses were recorded as the maximum threshold or 10 g, while 5 positive responses 
were recorded as the minimum threshold or 0.02 g.  The 50% threshold was calculated 
for each mouse and group means were determined as previous described (Chaplan, Bach 
et al. 1994).  Baseline behavior was measured before diabetes induction.  Afterwards, all 
animals were tested weekly for 6 weeks. 
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Tissue Preparation 
DRG were rapidly isolated and excised, immediately frozen in liquid nitrogen, 
and stored at -80oC.  DRG were sonicated for 5 intervals of 10 sec each  in 50 µL Cell 
Extraction Buffer (Invitrogen, Carlsbad, CA) with protease inhibitor cocktail (Sigma, St. 
Louis, MO), 200 mM NaF, and  200 mM Na3VO4.  The homogenates were incubated on 
ice for 30 mins before centrifugation at 7000 rpm for 10 mins at 4oC.  Protein 
concentrations were determined using the Bio-Rad protein assay based on the Bradford 
assay (Bio-Rad, Sydney, NSW, Australia). 
Glyoxalase I Expression 
Samples containing 100 µg of protein from total DRG homogenates were 
separated by electrophoresis through 4-20% SDS-PAGE gels (125 V, 1.5 h 4oC) and 
transferred onto nitrocellulose paper (35 mA, overnight, 4oC).  Nitrocellulose membranes 
were blocked with blocking buffer (3% non-fat milk and 0.05% Tween-20 in phosphate 
buffered saline) for 1 hour at room temperature to block non-specific binding sites.  This 
was followed by overnight incubation with a goat anti-GLO1 primary ntibody (R&D 
Systems, Minneapolis, MN) diluted 1:5000 in blocking buffer at 4oC.  The donkey anti-
goat IgG-HRP (Santa Cruz, Santa Cruz, CA) secondary antibody was used dilut d 1:2500 
in blocking buffer at RT for 1 hour.   
Nitrocellulose membranes were stripped using Restore Plus Western Blot 
Stripping Buffer (Pierce, Rockford, IL).  This was followed by 1-hour incubation with 
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actin primary antibody (Millipore, Billerica, MA) diluted 1:100,000 in blocking buffer at 
RT.  The donkey anti-mouse IgG-HRP secondary antibody (Santa Cruz, Santa Cruz, CA) 
was used diluted 1:2500 in blocking buffer at RT for 1 hour.  The chemiluminescent 
signal was acquired using Supersignal West Femto Maximum Sensitivity Substrate 
(Pierce, Rockford, IL) and a CCD camera (BioSpectrum Imaging System, UVP, Upland, 
CA).  Labworks Analysis Software (UVP, Upland, CA) was used to quantify 
densitometry readings. 
Glutathione Assay 
Total glutathione was measured using the Glutathione Assay Kit (Cayman 
Chemical, Ann Arbor, MI).  Briefly, the entire spinal cord from 8 week-old nondiabetic 
BALB/cByJ and BALB/cJ mice was dissected, rinsed in PBS, immediately frozen in 
liquid nitrogen, and stored at -80oC.  Tissues were homogenized in 5 mL of cold buffer 
(50 mM PBS, pH 6, containing 1 mM EDTA) per gram of tissue.  The samples were then 
deproteinated and the assay was performed according to the manufacturer’s protocol.  
Nerve Conduction Velocity 
Nerve conduction velocity was conducted as previously described on a Viasys 
Healthcare TECA Synergy (Stevens, Obrosova et al. 2000; Muller, Ryals et al. 2008).  
Animals were deeply anesthetized with Avertin (1.25% v/v tribromoethanol, 2.5% tert-
amyl alcohol, dH2O; 200 mg/kg body weight). Corneal reflexes were checked and body 
temperature was monitored and maintained at 37oC throughout the procedure.  Motor 
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nerve conduction velocities (MNCVs) were obtained by measuring compound muscle 
action potentials using supramaximal stimulation (9.9 mA) at the ankle distally and at the 
sciatic notch proximally.  The average of three independent recordings was obtained from 
the first interosseous muscle.  Sensory nerve conduction velocity (SNCV) was measured 
behind the medial malleolus with a 0.5-ms square wave pulse using the small st current 
to elicit a response (2.4 mA), stimulating at the digital nerve of the second toe.  SNCV 
was the average of 10 recordings. 
Intraepidermal Nerve Fiber Density 
Cutaneous innervation of the footpad was assessed in nondiabetic and diabetic 
mice after six weeks of diabetes.  The right footpad skin was harvested from mice at the 
time of sacrifice and immersion fixed in Zamboni’s fixative (4% paraformaldehyde, 14% 
saturated picric acid, 0.1 M phosphate buffered saline; pH 7.4) for 1 hour on ice.  
Footpads were washed in PBS twice and placed in PBS overnight at 4oC.  Footpads were 
then cryoprotected in 30% sucrose overnight at 4oC.  30 µm serial sections were cut and 
placed on Superfrost Plus microscope slides (Fischer, Chicago, IL).  
Immunohistochemistry was performed as previous described (Christianson, Ryals et al. 
2007; Johnson, Ryals et al. 2008).  Briefly, tissue sections were blocked in Primary 
Incubation Solution containing SuperBlock buffer (Pierce, Rockford, IL) with 1.5% 
normal donkey serum, 0.5% porcine gelatin, and 0.5% Triton X-100 for 1 hour at RT.  
Sections were then incubated in the primary antibody solution containing 1:1 Primary 
Incubation Solution and SuperBlock buffer with rabbit anti-PGP9.5 primary antibody 
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(1:400) overnight at 4oC.  A donkey anti-rabbit secondary antibody (Alexa 555, 1:2000,  
Molecular Probes, Eugene, OR) in 1X PBST was incubated for 1 hour at 4oC.  Small 
cutaneous, PGP9.5+ fibers that crossed the dermal-epidermal junction were quantified in 
three areas from three tissue sections from each footpad.  The length of the dermal-
epidermal junction was measured and intraepidermal nerve fiber density (IENFD) was 
expressed as the number of fibers per millimeter. 
Mitochondrial Enzyme Expression 
15 µg of protein from total DRG homogenates was separated by electrophoresis 
(150 V, 2 h, 4oC) on a 10-20% Tris-Glycine SDS-PAGE gels (Invitrogen, Carlsbad, CA) 
and transferred onto nitrocellulose paper (150 mA, 2 h, 4oC).  Membranes were blocked 
in 5% non-fat milk and 0.05% Tween-20 in phosphate buffered saline eitherovernight at 
4oC or 3 hours at RT.  An antibody cocktail against mitochondrial electron transport 
proteins (MS601, MitoSciences, Eugene, OR) was diluted 205X in 1% milk and 
incubated at RT for 2 h.. The donkey anti-mouse IgG-HRP (Santa Cruz, Santa Cruz, CA) 
secondary antibody was used diluted 1:2000 in blocking buffer at RT for 2 hours.  The 
chemiluminescence signal was acquired using Supersignal West Fem o Maximum 
Sensitivity Substrate (Pierce, Rockford, IL) and a CCD camera (BioSpectrum Imaging 
System, UVP, Upland, CA).  LabWorks Analysis Software (UVP, Upland, CA) was used 
to quantify densitometry readings.  All bands were normalized for actin expression. 
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Statistics 
Data are expressed as mean ± SEM.  n is the number of animals per given 
experimental setting.  Differences were analyzed using ANOVA followed by 
Bonferroni’s test, as appropriate.  Significance was defined as p ≤ 0.05. 
4. Results and Figures 
Blood Glucose and Weights 
More than 90% of mice of both strains injected with STZ developed diabetes 
shortly after injection.  As early as 1 week following STZ injection, diabetic mice 
displayed markedly increased blood glucose levels.  At the earliest time point, diabetic 
BALB/cByJ mice had an average blood glucose of 325.495 ± 15.943 mg/dl and iabetic 
BALB/cJ mice had an average blood glucose of 341.206 ± 19.735 mg/dl (Figure 1a).  
The elevated blood glucose persisted and worsened throughout the study with diabetic 
BALB/cByJ mice having an average blood glucose of 510.871 ± 19.737 mg/dl and 
diabetic BALB/cJ mice having an average blood glucose of 535.698 ± 12.120 mg/dl after 
6 weeks of diabetes (Figure 1a).  At all time points measured, diabetic mice from both 
strains had similar blood glucose levels that were not statistically different (Figure 1a).   
 Diabetic mice displayed other characteristic symptoms of hyperglycemia 
including polyuria, polydipsia, and limited weight gain.  Throughout the study, 
nondiabetic BALB/cByJ mice gained on average 6.9 ± 0.3 g and, similarly, nondiabetic 
BALB/cJ mice gained 5.6 ± 0.6 g (Figure 1b).  Conversely, diabetic mice had reduced 
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weight gain, as is characteristic of diabetic mouse models.  Diabetic BALB/cByJ gained 
2.1 ± 0.5 g from baseline, while diabetic BALB/cJ gained 0.2 ± 0.9 g (Fi ure 1b).  
Throughout the study, the average weight of diabetic mice was not significantly different 
between the two strains. 
Behavioral Measures 
 The responses of mice to von Frey monofilaments were used to determin  
mechanical sensitivity of the right hindpaw by measuring the 50% gram threshold 
weekly.  No difference existed in baseline behavioral measures between strains with 
thresholds of 2.429 ± 0.425 g for BALB/cByJ and 2.076 ± 0.323 g for BALB/cJ (p = 
0.5110) (Figure 2).  The baseline thresholds were similar for all four groups tested with 
nondiabetic BALB/cByJ mice, diabetic BALB/cByJ, nondiabetic BALB/cJ, and diabetic  
BALB/cJ having baseline thresholds of 2.152 ± 0.428 g, 3.119 ± 0.781 g, 2.975 ± 0.549 
g, and 1.389 ± 0.329 g, respectively.   
After five weeks of severe hyperglycemia, diabetic BALB/cJ mice develop 
increased mechanical thresholds that are indicative of insensate neuropathy (Figure 2).  
The 50% withdrawal threshold of diabetic BALB/cJ mice at five weeks after STZ 
injection was 5.899 ± 0.977 g, while nondiabetic BALB/cByJ and BALB/cJ mice had 
thresholds of 2.805 ± 0.581g and 1.888 ± 0.373 g, respectively.  Decreased mechanical 
sensitivity was also present after six weeks of diabetes in diabetic BALB/cJ mice 
reaching nearly a 77% increase from baseline.  Diabetic BALB/cJ mie at had  
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Figure 1:  Diabetic BALB/cByJ and BALB/cJ mice display characteristic features of 
diabetes including hyperglycemia and smaller body weight.   
Blood glucose (a) and weights (b) of nondiabetic and diabetic BALB/cByJ and BALB/cJ 
measured weekly for six weeks.  (a) Diabetic BALB/cByJ (gray circles, n = 15) and 
BALB/cJ (red triangles, n = 15) showed similar blood glucose measures each week, 
which was significantly different than nondiabetic BALB/cByJ (black circles, n = 10) and 
BALB/cJ (black triangles, n =10) (p < 0.0001).  (b) Diabetic BALB/cByJ (gray circles, n 
= 15) and diabetic BALB/cJ (red triangles, n = 15) had reduced weight gain compared to 
nondiabetic mice (black circles, BALB/cByJ, n =10 and black triangles, BALB/cJ, n = 
10) (p < 0.0001).  Data are presented as means ± SEM.  *p < 0.05 vs. nondiabetic 
BALB/cByJ mice.  ***p < 0.001 vs. nondiabetic BALB/cByJ mice.  ****p < 0.0001 vs. 
nondiabetic BALB/cByJ mice.  ##p < 0.01 vs. nondiabetic BALB/cJ mice.  ###p < 0.001 
vs. nondiabetic BALB/cJ mice.  ####p < 0.0001 vs. nondiabetic BALB/cJ mice. 
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Figure 2: Diabetic BALB/cByJ mice are protected from symptoms of neuropathy, 
while diabetic BALB/cJ mice develop symptoms insensate neuropathy. 
Behavioral responses to non-noxious mechanical stimuli were evaluated we kly in 
nondiabetic BALB/cByJ (black circles), diabetic BALB/cByJ (gray circles), nondiabetic 
BALB/cJ (black triangles), and diabetic BALB/cJ (red triangles) mice.  Baseline 
behavioral measurements were similar for all groups tested.  By 5 weeks after STZ 
induction, diabetic BALB/cJ (red n = 15) mice developed increased mechanical 
thresholds indicative of insensate neuropathy.  The mechanical thresholds of diabetic 
BALB/cByJ (n = 15) were not different from the thresholds of both nondiabetic strains (n 
= 10 each) at all time points suggesting diabetic BALB/cByJ are protected from 
neuropathy damage.  Data plotted as means ± SEM. *p < 0.05 vs. nondiabetic 
BALB/cByJ. *** p < 0.001 vs. nondiabetic BALB/cByJ.  ###p < 0.001 vs. diabetic 
BALB/cJ.  ††p < 0.01 vs. diabetic BALB/cByJ.  †††p < 0.001 vs. diabetic BALB/cByJ. 
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mechanical thresholds of 6.138 ± 0.945 g, while nondiabetic BALB/cByJ and BALB/cJ 
mice had thresholds of 2.362 ± 0.415 g and 2.022 ± 0.344 g, respectively.  This 
behavioral change is similar in time course and severity to that seen in STZ-treated 
C57BL/6 mice (Christianson, Ryals et al. 2007; Johnson, Ryals et al. 2008). 
Despite having significant hyperglycemia for six weeks, diabet c BALB/cByJ 
mice do not develop thresholds significantly different from baseline (Figure 2).  
Mechanical thresholds of diabetic BALB/cByJ mice are also not significantly different 
from nondiabetic BALB/cByJ or BALB/cJ at any time point.  On the other hand, diabetic 
BALB/cByJ mice had significantly lower thresholds compared to diabetic BALB/cJ mice 
at both five and six weeks post-STZ (2.739 ± 0.299 g vs. 5.899 ± 0.977g and 2.555 ± 
0.408 g vs. 6.138 ± 0.945 g). 
GLO1 Expression in Diabetes 
 After six weeks of diabetes, Western blots were used to determine GLO1 
expression differences between strains and the impact of diabetes on GLO1 levels.  
Nondiabetic BALB/cByJ mice had significantly higher expression of GLO1 in the DRG 
compared to nondiabetic BALB/cJ (1.000 ± 0.084 vs. 0.132 ± 0.097) (Figure 3).  Since 
GLO1 expression remained unchanged from nondiabetic levels following diabetes 
induction in both diabetic BALB/cJ and BALB/cByJ, diabetic BALB/cJ mice had 
significantly lower expression than diabetic BALB/cByJ mice (0.091 ± 0.001 vs. 0.852 ± 
0.134) (Figure 3). Combined, BALB/cByJ mice had 8-15-fold higher GLO1 expression 
compared to BALB/cJ mice. 
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Figure 3:  BALB/cByJ mice express higher levels of GLO1 compared to BALB/cJ 
mice.  
GLO1 expression in the DRG was measured by Western blot in nondiabetic (n = 3 each) 
and diabetic mice (n = 4 each) following 6 weeks of diabetes.  Nondiabetic BALB/cByJ 
mice express significantly higher levels of GLO1 compared to nondiabetic BALB/cJ 
mice.  Similarly, diabetic BALB/cByJ mice also have significantly higher expression of 
GLO1 compared to diabetic BALB/cJ mice.  Diabetes does not affect th  expression of 
GLO1 in either strain.  Diabetic BALB/cByJ and BALB/cJ mice show similar expression 
levels as their nondiabetic counterparts.  Data plotted as means ± SEM. *** p < 0.001 vs. 
nondiabetic Balb/cByJ.  ###p < 0.001 vs. diabetic Balb/cByJ. 
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Glutathione Measurement 
Total glutathione was measured in the whole spinal cord from 8 week-old 
nondiabetic BALB/cByJ and BALB/cJ (Figure 4).  Glutathione concentrations were not 
significantly different between the two strains.  Nondiabetic BAL /cByJ mice had 
glutathione concentrations of 0.291 ± 0.128 µM/mg protein and nondiabetic BALB/cJ 
mice had 0.206 ± 0.102 µM/mg protein in the spinal cord. 
Intraepidermal Nerve Fiber Density Following Diabetes Induction 
 After six weeks of diabetes, the pan-neuronal marker, PGP-9.5 was used to 
quantify cutaneous C-fibers in the hindpaw epidermis.  IENFD was similar between 
strains of nondiabetic mice (Figure 5a, b, and e).  Control BALB/cByJ mice had 80.3 ± 
5.3 fibers/mm in the right hindpaw which was no different from control BAL /cJ mice 
that had 89.3 ± 4.5 fibers/mm.  Conversely, diabetic BALB/cJ mice had 38% and 31% 
loss of cutaneous innervation compared to nondiabetic BALB/cJ and BALB/cByJ, 
respectively (Figure 5a, b, d, and e).  On the other hand, diabetic BALB/cByJ mice, 
which did not display mechanical deficits, showed IENFD similar to both nondiabetic 
strains (Figure 5 a, b, c, and e).  Thus, diabetic BALB/cJ mice also showed a 35% 
reduction of IENFD compared to diabetic BALB/cByJ mice.  
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Figure 4: Spinal cord glutathione concentration is not different between strains of 
diabetic mice.   
Glutathione was measured in the spinal cord of 10 week old nondiabetic BALB/cByJ 
(black bar) and BALB/cJ (white bar) by colorimetric assay.  Both strains had similar 
levels of glutathione (n = 3).  Data expressed as µM/mg of protein and plotted as means ± 
SEM. 
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Figure 5:  Intraepidermal nerve fiber density is reduced in diabetic BALB/cJ mice.   
Representative photomicrographs of skin from the right footpad of (a) nondiabetic 
BALB/cByJ, (b) nondiabetic BALB/cJ, (c) diabetic BALB/cByJ, and (d) diabetic 
BALB/cJ mice.  Diabetic BALB/cJ mice show a reduction in PGP9.5-positive cutaneous 
nerve fibers in the skin.  Scale bar = 10 µm.  (e)  Quantification of IENFD of nondiabetic 
BALB/cByJ (black bar, n = 5), diabetic BALB/cByJ (gray bar, n = 5), and nondiabetic 
BALB/cJ (white bar, n =5).  Diabetic BALB/cJ (red bar, n = 5) have a significant loss of 
cutaneous innervation after six weeks of diabetes.  Data plotted as means ± SEM.  ###p < 
0.001 vs. nondiabetic BALB/cJ.  *p < 0.05 vs. nondiabetic BALB/cByJ.  ††p < 0.01 vs. 
diabetic BALB/cJ. 
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Nerve Conduction Velocity 
 Both motor (MNCV) and sensory nerve conduction velocities (SNCV) were 
measured at the end of the six-week study in all four groups.  SNCV was not significantly 
different between any groups (p=0.055) (Figure 6a).  While nondiabetic BALB/cByJ and 
BALB/cJ mice had similar MNCV (50.825 ± 1.380 m/s vs. 55.120 ± 1.088 m/s, 
respectively), recordings identified motor dysfunction in both diabetic strains (Figure 6b).  
Diabetic BALB/cByJ mice had MNCVs of 42.456 ± 1.716 m/s, which was significantly 
lower compared to both nondiabetic BALB/cByJ and BALB/cJ strains.  However, 
diabetic BALB/cJ mice only had significant slowing of MNCV when compared to 
nondiabetic BALB/cJ mice.  The MNCV of diabetic BALB/cJ mice was similar to 
diabetic BALB/cByJ mice (Figure 6b). 
Mitochondrial Dysfunction 
 The expression of mitochondrial oxidative phosphorylation proteins was 
measured in the DRG to determine potential mechanisms leading to neuronal 
dysfunction.  No strain differences were apparent in the levels of Complex I subunit 
NDUFB8, Complex II FeS subunit, Complex III subunit Core 2, or Complex V subunit 
alpha between nondiabetic BALB/cByJ and BALB/cJ mice (Figure 7a, b, c, and d).  
Strikingly, Complex I expression was dramatically reduced in diabetic BALB/cJ 
compared to the other three groups (Figure 6d).  The expression of the NDUFB8 subunit 
was 83%, 81%, and 81% lower compared to nondiabetic BALB/cJ, nondiabetic 
BALB/cByJ, and diabetic BALB/cByJ, respectively (Figure 7d).  While Complex II and 
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III expression was not significantly different between groups (Figure 7b and c), Complex 
V was also reduced by 47% and 51% in diabetic BALB/cJ mice compared to nondiabetic 
BALB/cJ and diabetic BALB/cByJ mice (Figure 7a). 
5. Discussion 
In this study, two genetically similar strains of inbred mice that are natural genetic 
variants of GLO1 were used to investigate the potential role of GLO1 in development and 
modulation of diabetic neuropathy.  We have previously shown GLO1 is predominately 
expressed in small, unmyelinated peptidergic neurons in the DRG, suggestin  this DRG 
sensory neurons may be more or less vulnerable to hyperglycemia-da age depending on 
the level of GLO1 expression.  Here, our results reveal that BALB/cByJ mice have 
increased expression of GLO1 and are protected from the development of neur pathy 
symptoms following six weeks of hyperglycemia, while BALB/cJ mice develop 
increased mechanical thresholds and hypoalgesia characteristic of insensate neuropathy.  
Other parameters of neuron dysfunction are present in both diabetic strains including 
slowing of MNCV, however, only diabetic BALB/cJ mice display reduced C-fiber 
innervation of the hindpaw.  It is plausible to suggest that these anatomic l and behavior 
changes are a consequence of differential levels of reactive dicarbonyl-derived AGEs that 
modify mitochondrial oxidative phosphorylation structural proteins and lead to 
mitochondrial dysfunction (Brownlee 2005; Brouwers, Niessen et al. 2010).  
Collectively, these results suggest that reduced expression of GLO1 may prevent efficient  
 
117 
 
 
 
 
 
Figure 6:  Motor nerve conduction velocity (MNCV), but not sensory nerve 
conduction velocity (SNCV), is reduced in diabetic mice.   
Quantification of (a) SNCV and (b) MNCV in nondiabetic BALB/cByJ (black bars, n = 
10), diabetic BALB/cByJ (gray bars, n = 14), nondiabetic BALB/cJ (white bars, n = 10), 
and diabetic BALB/cJ (red bars, n = 7).  SNCV is not significantly different between 
groups.  However, MNCV is reduced in diabetic mice compared to their nondiabetic 
counterparts.  Data plotted as means ± SEM.   ***p < 0.001 vs. nondiabetic BALB/cByJ.  
#p < 0.05 vs. nondiabetic BALB/cJ. 
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Figure 7:  Mitochondrial oxidative phosphorylation proteins are reduced in diabetic 
BALB/cJ mice.  
The expression of proteins from mitochondrial oxidative phosphorylation complexes 
were measured in the DRG after six weeks of diabetes.  The expr ssion of structural 
components of complexes V (a), III (b), II (c), and I (a) were all accessed by Western blot 
in nondiabetic BALB/cByJ (black bars, n = 3), diabetic BALB/cByJ (gray bars, n = 3), 
nondiabetic BALB/cJ (white bars,  n = 3), and diabetic BALB/cJ (red bars, n = 3).  
Expression of both ATP synthase subunit α and Complex I subunit NDUFB8 were 
significantly reduced in diabetic BALB/cJ mice unlike diabetic BALB/cByJ mice.  #p < 
0.05 vs. nondiabetic BALB/cJ.  ##p < 0.01 vs. nondiabetic BALB/cJ.  *p < 0.05 vs. 
nondiabetic BALB/cByJ.  †p < 0.05 vs. diabetic BALB/cJ.   
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breakdown of reactive-dicarbonyl that cause mitochondrial damage, loss of peripheral C-
fiber innervation, and the development of mechanical insensitivity in diabetic neuropathy.   
 Numerous studies have shown overexpression of GLO1 to be protective against 
reactive dicarbonyl damage (Morcos, Du et al. 2008; Schlotterer, Kukudov et al. 2009; 
Brouwers, Niessen et al. 2010; Brouwers, Niessen et al. 2010; Gangadhariah, Mil nkot 
et al. 2010).  However, few studies have investigated the importance of GLO1 at 
physiological levels.  To our knowledge, this is the first to investigate variable expression 
in peripheral nerves and its role in the development of diabetic neuropathy.  A week after 
the onset of reduced mechanical sensitivity, GLO1 expression in the DRG of diabetic 
BALB/cJ mice remains similar to that of nondiabetic mice.  Although expression and 
activity in diabetes are likely species-, strain-, and tissue-dependent, our studies suggest 
that GLO1 expression is not altered by diabetes in the DRG of these two strains of inbred 
mice.  However, due to the known CNV, GLO1 expression in both nondiabetic and 
diabetic BALB/cJ mice is significantly lower than either nondiabetic or diabetic 
BALB/cByJ mice.  Higher expression of GLO1 may limit carbonyl stress and ultimately 
reduce AGE-mediated damage, at least early in the disease process.   
The loss of cutaneous nerve fibers, nerve conduction velocity, and behavioral 
measures have all been used to assess the presence of sensory nerve damage 
characteristic of diabetic neuropathy in both rodents and human patients.  Diabetic 
BALB/cJ mice develop loss of epidermal innervation, reduced nerve conduction 
velocities, and increased mechanical thresholds, as do majority of diabetic patients.  At 
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least early in the disease course, diabetic BALB/cByJ mice are protected from developing 
signs of diabetic neuropathy that diabetic BALB/cJ mice develop.  Similarly, a sizable 
percentage of patients, nearly 30-40%, do not develop classic overt neuropathy signs and 
symptoms even after years of diabetes mellitus.  Recently, a study of Joslin Gold 
Medalists, patients who have survived type I diabetes mellitus for ove 50 years, 
determined that glycemic control was unrelated to the development of diabetic 
complications (Sun, Keenan et al. 2011).  However, those patients with higher 
concentrations of AGEs, including methylglyoxal-derived N-(carboxyethyl)lysine, were 
2.5 times more likely to suffer from neuropathy (Sun, Keenan et al. 2011).  Those authors 
and others have suggested that certain patients may have an abundance of protective 
mechanisms that allow them to remain complication free. 
This suggests that underlying genetic differences in certain diabetic patients can 
protect against damage from methylglyoxal.  Since GLO1 is the major detoxification 
system of reactive dicarbonyls, it is plausible that differences in production and activity 
of the enzyme influences AGE production and the development and/or modulatin of 
diabetic neuropathy.  Studies have recognized various SNPs, null alleles, and CNVs of 
GLO1 in humans (Sparkes, Sparkes et al. 1983; Gale, Futers et al. 2004; Gale and Grant 
2004; Redon, Ishikawa et al. 2006).  While a number of studies have measured increased 
AGEs in diabetic patients in the skin and peripheral nerve (Sugimoto, Nishizawa et al. 
1997; Misur, Zarkovic et al. 2004; Meerwaldt, Links et al. 2005; Yu, Thorpe et al. 2006), 
limited investigation into the variability of protective mechanisms, particularly in these 
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tissues, has occurred and may help explain why some patients develop diabetic 
neuropathy and others do not.    
Investigation into early signs and symptoms of neuronal dysfunction is critical to 
understanding the mechanisms driving the pathogenesis of diabetic neuropathy.  A week 
after the onset of reduced mechanical sensitivity in diabetic BALB/cJ mice, the 
expression of structural components of mitochondrial oxidative phosphorylatin proteins 
Complex I and V is dramatically reduced.  Evidence linking reactive dicarbonyls with 
mitochondrial dysfunction has been mounting (Rabbani and Thornalley 2008).  In a C. 
elegan model of aging, the reactive dicarbonyl-derived AGE, MG-H1, modifie  
mitochondrial proteins leading to increased ROS which was attenuated wi h GLO1 
overexpression (Morcos, Du et al. 2008).  In vitro investigation utilizing a neuroblastoma 
cell line found ATP and mitochondrial membrane potential were both reduced following 
exposure to methylglyoxal (de Arriba, Stuchbury et al. 2007).  Further evidence 
suggesting increased GLO1 expression protects against mitochondrial damage was 
recently published utilizing a transgenic rat model overexpressing GLO1.  Diabetic 
transgenic rats showed increased GLO1 expression, reduced levels of plasma reactive 
dicarbonyls and AGEs, and higher expression of mitochondrial oxidative phosphorylation 
proteins compared to wild type diabetic rats (Brouwers, Niessen et al. 2010)  
Mitochondrial dysfunction has also been implicated in the pathogenesis of 
diabetic neuropathy.  Similar to our data, Chowdhury et al. observed reduced expression 
of NDUFS3, one component of the iron-sulfur protein of Complex I, in STZ-diabetic rats 
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(Chowdhury, Zherebitskaya et al. 2010).  They have also observed alterations in other 
mitochondrial proteins, including components of oxidative phosphorylation including 
ATP synthase (Akude, Zherebitskaya et al. 2011).  Functionally, rates of r piration and 
activity of oxidative phosphorylation complexes are reduced in in the peripheral nervous 
system of diabetic rats that result from proteome alterations (Chowdhury, Zherebitskaya 
et al. 2010).  With evidence linking oxidative phosphorylation proteins modified by 
reactive dicarbonyls with mitochondrial dysfunction, diabetic BALB/cByJ mice could be 
protected from these proteome alterations due to increased GLO1 production.  Thus, 
genetic differences in protective mechanisms, particularly of GLO1, could play a role in 
preventing early mitochondrial dysfunction that causes sensory neuron damage and 
diabetic neuropathy symptoms. 
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CHAPTER 5 
Mitochondrial Oxidative Phosphorylation Proteins Are Reduced Following In Vitro 
Methylglyoxal Treatment of Sensory Neurons 
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1. Abstract 
 Altered mitochondrial function has been implicated in the development of many 
neurological disorders.  Recently, mitochondrial stress and dysfunction have been 
recognized in sensory neurons and Schwann cells from diabetic rodents and clinically in 
cases of neuropathy; however the cause and implications of this dysfunction remain 
unknown.  In this study, cultured adult sensory neurons from nondiabetic animals were 
treated with methylglyoxal.  Methylglyoxal was not overtly to toxic sensory neurons and 
did not result in neuronal death.  However, methylglyoxal treatment r sulted in 
significant reduction in the expression of mitochondrial oxidative phosrylation 
proteins in C57BL/6 mice.  However, similar treatment did not result in altered 
expression of mitochondrial oxidative phosphorylation proteins in BALB/cByJ or 
BALB/cJ.  These results suggest that alterations in the mitochondrial proteome due to 
increased reactive dicarbonyls, particularly mitochondrial oxidative phosphorylation 
proteins, could underlie sensory neuron dysfunction and have a role in the development 
of hyperglycemia-induced axonopathy in diabetic neuropathy. 
2. Introduction 
 Mitochondria function in wide range of critical cellular pathways including fatty 
acid breakdown, calcium homeostasis, oxidative phosphorylation, and energy production, 
all of which are required for proper neuronal function (Mattson, Gleichmann et al. 2008; 
Luce, Weil et al. 2010; Pickrell and Moraes 2010).  Consequently, neurons are e pecially 
sensitive and vulnerable to alterations of normal mitochondrial function (Ha , Tomizawa 
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et al. 2011).   Mitochondrial dysfunction has been recognized in numerous neurological 
disorders (Mattson, Gleichmann et al. 2008). It has also become an increasi gly 
recognized and clinically important mechanism in the development of peripheral 
neuropathies, which suggests diabetic neuropathy could also result from mitochondrial 
damage in sensory neurons (Mattson, Gleichmann et al. 2008; Feely, Laura et al. 2011; 
Lehmann, Chen et al. 2011).  Oxidative phosphorylation defects have been recog iz d in 
secondary complications of diabetes mellitus, such as nephropathy and cardiomyopathy, 
however, investigation into alterations of the mitochondrial proteome in diabetic 
neuropathy has severely lagged behind. 
 Several studies have shown reactive dicarbonyls target and modify mitochondrial 
proteins including oxidative phosphorylation proteins and can result in reduced 
expression of these complexes (Rosca, Mustata et al. 2005; Morcos, Du et al. 2008; 
Brouwers, Niessen et al. 2010).  Indeed, in Chapter 4, our results revealed th t 
mitochondrial oxidative phosphorylation protein expression was blunted in DRG from 
diabetic BALB/cJ mice that have low levels of GLO1 and develop increased mechanical 
thresholds. On the other hand, diabetic BALB/cByJ mice, which haveigher levels of 
GLO1, were protected from sensory neuron dysfunction and perturbations of 
mitochondrial oxidative phosphorylation complexes.  In support of these findings, this 
study set out to determine if cultured sensory neurons were vulnerab e to methylglyoxal-
induced reductions of mitochondrial oxidative phosphorylation complexes. 
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3. Experimental Procedures 
Animals 
 All experiments were approved by the University of Kansas Medical Center 
Institutional Animal Care and Use Committee in accordance with NIH guidelines and 
Animal Care and Use Protocol.  Male C57BL/6 (Charles River, Wilmington, MA), 
BALB/cByJ, and BALB/cJ (Jackson Laboratories, Bar Harbor MA) were purchased at 8 
weeks of age.  Animals were house in 12/12-h light/dark cycle under pathogen free 
conditions. 
Adult DRG Culture 
 Mice were anesthetized with avertin (1.25% v/v tribromoethanol, 2.5% tert-amyl 
alcohol, dH2O; 200 mg/kg body weight) and transcardially perfused with ice-cold Hank’s 
Buffered Salt Solution (HBSS; Sigma Aldrich).  DRG were harvested and transferred to 
HBSS without Ca2+/Mg2+.  Culture conditions were performed in accordance with 
previously published protocols (Malin, Davis et al. 2007).  DRG were partially digested 
with papain (Worthington; Lakewood, NJ) solution followed by digestion with 
collagenase type II (Worthington, Lakewood, NJ)/dispase  (Roche; Basel, Switzerland) 
solution.  Sensory neurons were titurated with a fire-polished glass P teur pipette to 
dissociate neuronal cell bodies.  Neurons were grown on Laminin/poly-D-lysine coated 
coverslips (BD Biosciences; Bedford, MA) placed in 24 well culture plates (Sigma 
Aldrich) for viability studies.  For western blot analysis, neurons were grown in 
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Laminin/poly-D-lysine coated 6-well plates (BD Biosciences; Bedford, MA).  F12 
culture medium (Invitrogen; Carlsbad, CA) was supplemented with 1X B27 minus 
antioxidant supplement (Invitrogen) and 1,000 U/ml penicillin/streptomycin antibiotics.  
Cultures were maintained at 37oC and 5% CO2.   
Methylglyoxal Treatment 
 Methylglyoxal (Sigma Aldrich) was diluted to 100 mM in steril H2O and 
maintained at 4oC.  For low dose culture treatments, F12 media supplemented with 1X 
B27 minus antioxidants and antibiotics was prepared with methylglyoxa  diluted to the 
working concentration (5, 10, 15, 20, of 25 µM).  For high dose culture treatments, F12 
media with antibiotics only was prepared with methylglyoxal diluted to 100 µM.  Control 
wells received media only.  Media was replaced with medium containi g methylglyoxal 
12-18 hours after initial culturing.  Cultures were treated for 24 hours total with the media 
being replaced after 12 hours of treatment to maintain methylglyoxal concentrations. 
LIVE/DEAD Assay 
 The LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen) was used to determine 
neuronal viability following methylglyoxal treatment.  After 24 hour methylglyoxal 
treatment, coverslips were washed with D-PBS (Sigma Aldrich).  Coverslips were then 
covered with LIVE/DEAD solution containing 2 mM EthD-1 and 4 mM calcein AM for 
30 minutes.  Coverslips were mounted on slides and imaged.  Live (green) and dead (red) 
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neurons were counted in six frames from each coverslip.  Three coverslips per treatment 
were counted. 
Western Blot 
 Cultures were washed three times with D-PBS before harvesting protein.  Cell 
Extraction Buffer (Invitrogen) containing protease inhibitor cocktail (Sigma, St. Louis, 
MO), 200 mM NaF, and 200 mM Na3VO4 was added to the wells and cells were 
harvested using a cell scraper.  Samples were then incubated on ice f r 30 minutes with 
light vortexing every 5 minutes followed by centrifugation at 7000 rpm for 10 minutes at 
4oC.  Amicon Ultra-0.5 mL Centrigugal Filters (Millipore; Billerica, MA) were used to 
concentrate protein samples.  Following concentration, protein concentrations were 
determined with a Bradford assay (Bio-Rad; Hercules, CA).  10 µg of protein were 
separated by electrophoresis (150 V, 2 h, 4oC) on a 10-20% Tris-Glycine SDS-PAGE 
gels (Invitrogen, Carlsbad, CA) and transferred onto nitrocellulose paper (150 mA, 2 h, 
4oC). 
For fluorescent Western blot detection, immunoblots were blocked in Odyssey 
Blocking Buffer (LI-COR Biosciences; Lincoln, NE) for 1 h at RT followed by overnight 
incubation with a rabbit anti-actin (Millipore; 1:1000) primary antibody at 4oC in 
blocking buffer.  The IR Dye 800 anti-rabbit antibody (Rockland; 1:1000) and Odyssey 
infrared imaging system (LI-COR) were used to detect the fluorescence signal.  
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To detect mitochondrial oxidative phosphorylation proteins, membranes were 
then blocked in 5% non-fat milk and 0.05% Tween-20 in phosphate buffered saline for 3 
hours at RT.  An antibody cocktail against mitochondrial electron tra sport proteins 
(MS601, MitoSciences, Eugene, OR) was diluted 208X in 1% milk and incubated at RT 
for 3 h..  The donkey anti-mouse IgG-HRP (Santa Cruz, Santa Cruz, CA) secondary 
antibody was used diluted 1:1000 in blocking buffer at RT for 2 h.  Membranes were also 
incubated with either rabbit anti-Akt (Cell Signaling; Danvers, MA; 1:000) or rabbit anti-
neurofilament L (Cell Signaling; 1:1000) for 1 h at RT.  The donkey anti-r bbit IgG-HRP 
(Santa Cruz) secondary antibody was used diluted 1:1000 in 1% milk at RT for 1 h.  The 
chemiluminescence signal was acquired using Supersignal West Fem o Maximum 
Sensitivity Substrate (Pierce, Rockford, IL) and a CCD camera (BioSpectrum Imaging 
System, UVP, Upland, CA).  LabWorks Analysis Software (UVP, Upland, CA) was used 
to quantify densitometry readings.  All measurements were normalized to a housekeeping 
gene. 
Statistics 
Data are expressed as mean ± SEM.  Differences were analyzed using Student’s 
T-test or ANOVA followed by Bonferroni’s test, as appropriate.  Significance was 
defined as p ≤ 0.05. 
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4. Results and Figures 
Viability of Cultured Sensory Neurons After Low Dose Methylglyoxal Treatment 
 To determine if methylglyoxal was significantly toxic to cells, neuronal survival 
was measured following methylglyoxal treatment.  Primary cultures of adult sensory 
neurons from nondiabetic C57BL/6 mice were treated with 0, 5, 10, 15, 20, or 25 µM 
methylglyoxal.  The viability of neurons following methylglyoxal treatment was not 
significantly impaired (Figure 1a and 1b).  Sensory neurons had a survival of 98% ± 1 
following treatment with the highest concentration of methylglyoxal (25 µM). 
Expression of Mitochondrial Oxidative Phosphorylation Proteins Following Low Dose 
Methylglyoxal Treatment of Sensory Neurons from C57BL/6 Mice 
 To determine if methylglyoxal has an effect on the expression of oxidative 
phosphorylation proteins, DRG sensory neurons were treated with low dose 
methylglyoxal.  Following 24-hour methylglyoxal treatment, the expr ssion of 
mitochondrial oxidative phosphorylation proteins was determined in C57BL/6 sensory 
neurons by Western blot. The expression of structural components of Complex V, III, II, 
and I were not altered following low dose methylglyoxal treatment (Figure 2).   
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Figure 1: Sensory neurons survival methylglyoxal treatment 
Cultured C57BL/6 sensory neuron viability was accessed following treatment with (a) 0, 
5, 10, 15, 20, and 25 µM methylglyoxal for 24 hours.  Live (green) and dead (red) cells 
were counted as shown in the photomicrographs and the percent viability was calculated.  
(b) Quantification of the percent viability for each treatment. Scale bar; 50 µM. 
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Figure 2: Mitochondrial oxidative phosphorylation protein expression following 24 
hours with low dose methylglyoxal treatment 
Cultured sensory neurons from C57BL/6 mice were treated with 0, 5, 10, 15, 20, and 25 
µM methylglyoxal for 24 hours.  Mitochondrial oxidative phosphorylation proteins were 
measured by Western blot.  (a) Complex V, (b) Complex III, (c) Complex II, and (d) 
Complex I intensities were normalized to Akt. 
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High Dose Methylglyoxal Treatment of Sensory Neurons from C57BL/6 Mice 
 Since low dose methylglyoxal treatment did not show changes in the expression 
of oxidative phosphorylation proteins, the concentration of methylglyoxal was increased 
to 100 µM and oxidative phosphorylation proteins were measured.  Following 4-hour 
treatment with high dose methylglyoxal, Complex I, II, and III showed modest reductions 
(Figure 3).  Consequently, cultured sensory neurons were then treated with higher dose 
methylglyoxal for 24 hours.  After 24 hours, sensory neurons from C57BL/6 mice treated 
with 100 µM methylglyoxal showed significant reductions in the expression of Complex 
V, III, and II structural proteins (Figure 4).  Complex V, III, and II were reduced by 13%, 
31%, and 42%, respectively.  Importantly, viability was not different in the high dose 
treated DRG sensory neurons compared to control (Figure 5). 
High Dose Methylglyoxal Treatment of Sensory Neurons from BALB/cByJ and BALB/cJ 
Mice 
 Since BALB/cByJ and BALB/cJ express different amounts of GLO1, we used 
cultured sensory neurons from these two strains to determine if el vated levels of GLO1 
would protect against methylglyoxal-induced reductions in the expression of oxidative 
phosphorylation proteins.  Following 24 hour treatment with 100 µM methylglyoxal, 
neither BALB/cByJ nor BALB/cJ mice displayed altered expression of structural proteins 
from oxidative phosphorylation complexes (Figure 6). 
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Figure 3: Mitochondrial oxidative phosphorylation protein expression following 4 
hours with high dose methylglyoxal treatment 
Cultured sensory neurons from C57BL/6 mice were treated with 0 or 100 µM 
methylglyoxal for 4 hours in supplement free media.  Mitochondrial oxidative 
phosphorylation proteins were measured by Western blot.  (a) Complex V, (b) Complex 
III, (c) Complex II, and (d) Complex I intensities were normalized to neurofilament L.  
Actin was used to confirm neurofilament L as a loading control. 
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Figure 4: Mitochondrial oxidative phosphorylation protein expression following 24 
hours with high dose methylglyoxal treatment 
Cultured sensory neurons from C57BL/6 mice were treated with 0 or 100 µM 
methylglyoxal for 24 hours.  Mitochondrial oxidative phosphorylation proteins were 
measured by Western blot.  (a) Complex V, (b) Complex III, (c) Complex II, and (d) 
Complex I intensities were normalized to neurofilament L. 
 
 
 
 
 
 
141 
 
 
Figure 4 
 
 
142 
 
 
 
 
 
 
Figure 5: Sensory neuron survival following 24 hour treatment with high dose 
methylglyoxal 
Cultured sensory neurons from C57BL/6 mice were treated with 0 or 100 µM 
methylglyoxal for 24 hours.  (a) Representative photomicrographs of live (green) and 
dead (red) cells.  (b) Quantification of cultured sensory neuron viability fo lowing 24 
hour treatment with 100 µM methylglyoxal. 
 
 
 
 
 
 
143 
 
Figure 5 
 
 
 
144 
 
 
 
 
 
 
Figure 6: Mitochondrial oxidative phosphorylation protein expression in sensory 
neuron cultures from BALB/cByJ and BALB/cJ mice following 24 hours with high 
dose methylglyoxal treatment 
Cultured sensory neurons from BALB/cByJ (black bars) and BALB/cJ (white bars) mice 
were treated with 0 or 100 µM methylglyoxal for 24 hours.  Mitochondrial oxidative 
phosphorylation proteins were measured by Western blot.  (a) Complex V, (b) Complex 
III, (c) Complex II, and (d) Complex I intensities were normalized to neurofilament L. 
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5. Discussion 
 Reactive dicarbonyls, such as methylglyoxal, have been show to target and impair 
components of the mitochondrial oxidative phosphorylation pathway (Rosca, Mustata et 
al. 2005; Morcos, Du et al. 2008; Schlotterer, Kukudov et al. 2009).  In our previous 
study in Chapter 5, reduced expression of GLO1 correlated with the dev lopment of 
mechanical insensitivity, loss of epidermal innervation, and reduced expression of 
structural proteins from Complex V and I of the mitochondrial oxidative phosphorylation 
cascade.  This study suggested that increased levels of reactive dicarbonyls due to STZ-
induced diabetes, presumably due to reduced GLO1 expression, may modify components 
of these complexes, alter the expression levels, and subsequently lead to mitochondrial 
dysfunction and altered neuronal function. 
 In this study, methylglyoxal treatment of cultured sensory neurons from 
nondiabetic C57BL/6 mice was used to assess the vulnerability of mit chondrial 
oxidative phosphorylation proteins to methylglyoxal.  Initial studies using low levels of 
methylglyoxal had no effect on the expression of mitochondrial proteins.  This low dose 
treatment included B27 minus antioxidants in the medium to negate the influ nce of high 
levels of glutathione while still providing neurons with necessary nutrients.  However, 
this supplement also contains high levels of protein, including bovine serum albu in.  
Consequently, negative results could be attributed to the high reactivity of methylglyoxal 
and the probability of reacting with the elevated levels of exogenous protein.  Similarly, it 
is important to note that majority of in vitro studies that treat different cell types with 
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reactive dicarbonyls typically do so at much higher doses including micromolar 
concentrations (Rosca, Monnier et al. 2002; de Arriba, Stuchbury et al. 2007; Huang, 
Chuang et al. 2008; Mukohda, Yamawaki et al. 2009).   
 Subsequent investigation utilized higher dose methylglyoxal and supplement fre  
media. Again, the concentration of methylglyoxal utilized in these studies was still far 
less than other studies.  However, DRG neurons cultured from C57BL/6 mice resulted in 
reduced oxidative phosphorylation protein abundance.  Importantly, the higher dos  of 
methylglyoxal did not impair the viability of DRG sensory neurons.  Previous in vitro 
studies on embryonic DRG neurons under hyperglycemic conditions suggested a k y 
feature of neuronal degeneration included apoptosis (Vincent, Stevens et al. 2005; 
Zherebitskaya, Akude et al. 2009).  Apoptosis was then erroneously characterized as a 
key feature underlying fiber loss in diabetic neuropathy, which was subsequently 
disproven using adult DRG neurons (Zherebitskaya, Akude et al. 2009).  Similarly, 
treatment of neuroblastoma cells with methylglyoxal or inhibition of GLO1 resulted in 
apoptosis (Kuhla, Luth et al. 2006; de Arriba, Stuchbury et al. 2007); however, in our 
study, methylglyoxal impairs the mitochondrial proteome but it does not result in 
neuronal death. 
 Finally, we cultured sensory neurons from two strains of mice that have different 
levels of GLO1 expression, as characterized in Chapter 4.  Due to lower GLO1 
expression, we anticipated BALB/cJ mice would be more vulnerable to me hylglyoxal 
treatment and have reduced oxidative phosphorylation protein expression, while 
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BALB/cByJ mice would be protected.  However, this study showed methylglyoxal 
treatment did not impair mitochondrial proteins in DRG neurons from the BALB/cJ 
substrain.  It is plausible that differences in glutathione levels b tween BALB/cJ and 
C57BL/6 mice could explain the divergent results.  Also, the threshold at which 
methylglyoxal treatment results in altered mitochondrial proteins could be different 
between the two strains. 
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Conclusions 
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 Diabetes-induced hyperglycemia causes metabolic derangement of the peripheral 
nervous system resulting in diabetic peripheral neuropathy.  Sensory eu on damage 
manifests as cutaneous fiber loss, altered nerve conduction, and altered sensation to 
various stimuli.  Diabetic neuropathy can lead to debilitating pain or the loss of protective 
sensation; however, some diabetic patients do not experience altered sensation or nervous 
system complications.  An understanding of why certain symptoms, either painful or 
painless, develop in patients and why others are protected from damage to the peripheral 
nervous system remains elusive. 
 The purpose of this study was to elucidate the relationship between diff rential 
GLO1 expression in the peripheral nervous system, the development and/or progression 
of diabetic neuropathy, and pathological mechanisms that may underlie hyperglycemia-
induced sensory neuron dysfunction with reduced protective mechanisms in diabetes 
mellitus.  In pursuit, studies in this dissertation characterized th  pattern of expression of 
GLO1 in the peripheral nervous system, utilized numerous inbred strains of mice that 
vary in their GLO1 expression due to a known copy number variant to assess various 
sensory modalities following diabetes induction, and investigated alterations of the 
mitochondrial oxidative phosphorylation complexes as a mechanism of sensory neuron 
dysfunction.   
Chapter 2: Characterization of glyoxalase I in the peripheral nervous system 
 While all accounts in the literature characterize GLO1 as having a ubiquitous 
presence in all cells of the body, our findings suggest that GLO1 has a much more 
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restricted pattern in the nervous system.  Immunohistochemical studie  revealed GLO1 
was primarily expressed in small peptidergic neurons that function in thermal, 
mechanical, and pain transmission from the periphery.  Investigation of different inbred 
strains of mice also revealed GLO1 expression was quite variable in the DRG and other 
tissues of the peripheral and central nervous system, which is a consequence of either 
duplication or loss of the region of the genome encompassing GLO1. 
 While these results have clear functional relevance in the peptidergic 
subpopulation of nociceptive C-fibers, the seeming lack of GLO1 in other populations of 
sensory neurons is also intriguing.  This seems to suggest one of two concepts: either 
these other populations of sensory neurons rely on other mechanisms to detoxify r active 
dicarbonyls besides the glyoxalase system or these fiber types are particularly vulnerable 
to elevated intracellular glucose and reactive dicarbonyl-mediated damage.  As discussed 
in this dissertation, other minor pathways have been recognized that have the ability to 
recognize and breakdown reactive dicarbonyls, but do not have as much specificity for 
reactive dicarbonyls or the efficiency as GLO1 does.  It is likely these populations rely on 
other detoxification systems given the clear deleterious nature of reactive dicarbonyl and 
AGE accumulation.  However, what these systems are, how efficient these are, and how 
they are affected in diabetes is entirely unknown.  Clearly, further understanding these 
differences in sensory neurons would lead to a better understanding of the secondary 
mechanisms of hyperglycemia-induced damage that target specific fiber types and reveal 
novel therapeutic targets based on the signs and symptoms of a patient, i.e. fiber types 
affected. 
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 As emphasized throughout this dissertation, majority of diabetic patients will 
develop signs and symptoms of diabetic neuropathy throughout the course of the disease.  
However, a minority of patients, between 30-40%, do not develop sensory complications.  
The interesting question is what makes these patients different.  With regards to this 
dissertation, it is plausible these patients have an abundance of protective mechanisms, 
such as GLO1, that can limit the toxic effects of hyperglycemia.  The recent study 
highlighting the Joslin 50-year medalists is a clear example of a patient population that is 
enriched in these protective mechanisms and investigating the genetics underlying this 
protection could lead to improved screening techniques and biomarkers that predict the 
development of diabetic neuropathy (Sun, Keenan et al. 2011).   
 Another important aspect that could benefit patients clinically is determining 
CNV, SNPs, regulatory factors, and genetic alterations that lead to reduced expression or 
activity of GLO1 in human patients.  Recently, two studies have highlighted the 
importance of conducting these studies by showing that both SNPs in the coding region 
and in the promotor region of GLO1 reduced the activity in patients with autism and type 
II diabetic patients with retinopathy and nephropathy, respectively (Barua, Jenkins et al. 
2011; Wu, Li et al. 2011).  As previously mentioned, GLO1 was recognized as a CNV in 
a large screen of the human genome.  However, to date, no investigation nto the nature 
or abundance of this genetic finding in healthy patient populations or diabetic patients 
with or without neuropathy has occurred.  Again, studying both of these asp cts of 
protection likely would improve our understanding of diabetic neuropathy, improve 
screening in patients, and develop novel drug targets for improved treatments. 
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 While we have characterized GLO1 expression in the nervous system of inbred 
strains of mice and type I diabetic models, GLO1 has only been characterized in the 
kidney of type II diabetic rodents.  Since type II diabetes is far more prevalent than type I 
diabetes, it would be interesting to measure the expression level, expression pattern, and 
activity in the peripheral nervous system of type II diabetic animals, including ob/ob and 
db/db mice.  While both of these strains are on a C57BL/6 background, alterations in 
GLO1 expression or activity following insulin resistance and development of diabetes is 
particularly interesting given these two strains develop different signs of diabetic 
neuropathy. 
Chapter 3: Characterization of Glyoxalase I in Mouse Models of Painful and 
Insensate Diabetic Neuropathy 
 Since peptidergic neurons are known to have a role in pain transmission and 
previous work in our laboratory recognized the onset of mechanical and thermal 
insensitivity correlated with the loss of peptidergic neurons, the exclusive expression of 
GLO1 in this population of dorsal root ganglion neurons suggested it may have a role in 
protecting this subpopulation from reactive dicarbonyl-mediated damage depending on 
the strain and the level of GLO1 expression.  In this study, we characterized both the 
development of sensory deficits in diabetic A/J and C57BL/6 mice and GLO1 expression 
in these strains.  The development of reduced mechanical and thermal sensitivity 
correlated with reduced GLO1 expression in diabetic C57BL/6 mice.  Surprisingly, 
diabetic A/J mice that have high levels of GLO1 developed reduced mechanical 
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thresholds indicative of painful neuropathy.   These results suggest that an imbalance of 
fiber types may underlie the development of dichotomous signs and symptoms of diabetic 
neuropathy. 
 Future studies investigating a correlation between loss of specific fiber types and 
development of either increased or decreased sensory thresholds would be beneficial.  
The MrgD mice are a beneficial tool for accomplishing this study.  By developing A/J 
mice that express GFP in nonpeptidergic C-fibers would enable improved detection of 
specific fiber types that are lost in painful diabetic neuropathy.  This would determine if 
an imbalance of fiber types underlies the development of insensate and/or painful 
neuropathy. 
Chapter 4: Elevated Glyoxalase I Expression Provides Protection From Diabetes-
Induced Peripheral Neuropathy 
 To determine the role of GLO1 in the presentation and/or progression of sensory 
deficits and hyperglycemia-induced damage, two BALB/c substrains that have similar 
genetic backgrounds but maintain differential expression of GLO1 were utilized.  In this 
study, diabetic BALB/cByJ mice that have highest expression of GLO1 were protected 
from alterations of mechanical thresholds, loss of epidermal innervation, and changes in 
the expression of mitochondrial electron transport chain proteins.  Oppositely, diabetic 
BALB/cJ mice with reduced expression of GLO1 showed increased mechanical 
thresholds, loss of epidermal fibers, and reduced expression of certain mi ochondrial 
oxidative phosphorylation proteins.  Our findings nicely support previous data from 
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diabetic rats showing similar reductions of the mitochondrial proteome without an 
increase in oxidative stress (Akude, Zherebitskaya et al. 2011). 
 Our studies using BALB/c substrains investigated mechanism of neuronal dam ge 
shortly after the onset of behavior changes in mechanical sensitivity.  Thus, at least after 
six weeks of diabetes, BALB/cByJ mice were protected from developing changes in 
mechanical sensation since the mechanical thresholds of these mice were not different 
from nondiabetic animals.  Future studies should follow the same experimental design, 
but extend the studies to longer time points to determine if BALB/cByJ mice are only 
protected in the early stages of diabetes or all together resistant against developing 
diabetic neuropathy. 
 While these two BALB/c substrains are very similar, they do have documented 
differences.  To confirm our findings, a conditional knockout of GLO1 in peptidergic 
neurons on a BALB/cByJ background or overexpression in BALB/cJ mice would be 
beneficial.  Other experiments could use an in vivo lentivirial shRNA knockdown in the 
dorsal root ganglia of diabetic BALB/cByJ mice to determine if indeed elevated levels of 
reactive dicarbonyls in this strain would produce similar sensory deficits and h llmarks of 
diabetic neuropathy that we measured in diabetic BALB/cJ mice. 
 While hyperglycemia has a clear role in the pathogenesis of diabetic neuropathy, 
environmental factors likely also have a role in modulating or exacerb ting signs and 
symptoms of diabetic neuropathy.  Thus, examining both GLO1 levels and reactive 
dicarbonyl concentrations in the peripheral nervous system following exercise or high fat 
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diet administration in a type I diabetic model would determine if outside factors have an 
influence on this pathway implicated in the development of diabetic neuropathy.  These 
studies would have direct clinical relevance in advising patients with diabetes which 
factors may increase or decrease their risk for developing diabetic neuropathy. 
 It also remains to be determined if the increased physiological expression of 
GLO1 is capable at preventing increased concentrations of reactive dicarbonyls and 
accumulation of AGEs in the setting of diabetes mellitus.  Thus, measuring reactive 
dicarbonyls, such as methylglyoxal, glyoxal, and 3-deoxyglucose, and AGEs would be 
beneficial to determine if the increased levels of GLO1 are indeed protective.  Similarly, 
characterizing proteins that are modified by methylglyoxal and other reactive 
dicarbonyls, particularly mitochondrial proteins, would be advantageous.  While a 
number of proteins have been identified as targets for reactive dicarbonyls and explain 
various aspects of cellular dysfunction, proteins modified in diabetic s nsory neurons 
have yet to be determined.  Therefore, experiments using proteomic techniques and 
designed to measure proteins modified by methylglyoxal would provide better 
understanding of the pathogenesis of diabetic neuropathy. 
 It would also be interesting to determine if reduced expression of mit chondrial 
oxidative phosphorylation protein in the BALB/cJ model results in oxidative stress in 
sensory neurons.  Though questions are arising in the field where precisely oxidative 
damage occurs in the neuron and what mechanism produces these reactive oxygen 
species, sensory neurons from diabetic rats show reduced activity of mitochondria that do 
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not produce increased reactive oxygen species.  This is contrary to a number of findings 
in other diabetic tissues suggesting the pathogenic mechanisms believed to occur in all 
tissues that are prone to secondary complications may indeed not be the case and tissue 
specificity may be important at elucidating these mechanisms. 
 Also, sensory neurons from type II diabetic mouse models have displayed altered 
biogenesis, fission, and morphology of mitochondria indicating hyperglycemia triggers 
physiological changes of cellular energy production.  It would be interesting to determine 
if any of these parameters were different between the two substrains.  This would suggest 
that reactive dicarbonyl damage may result in other measures of mit chondrial 
dysfunction and GLO1 may protect against more global damage to these organelles.  
Similarly, isolating mitochondria from the cell body and the peripheal terminals of 
sensory neurons from these two strains would determine if reduced GLO1 expression 
makes mitochondria in the periphery more susceptible to damage as compared to those in 
the cell body. 
 Finally, our findings from this study suggest elevated GLO1 maybe protective in 
the peripheral nervous system.  Consequently, the development of small molecules that 
target GLO1 and increase its activity could have therapeutic benefit i  diabetic 
neuropathy.  Unfortunately, drug discovery has mainly focused on inhibitors of GLO1 
due to its necessary role in cancer cells and in the development of multi-drug resistance.  
A recent study using Akita mice, a spontaneous type I diabetic model, f und fisetin, a 
rare flavone, increased GLO1 levels and activity and increased th synthesis of 
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glutathione (Maher, Dargusch et al. 2011).  Treatment reduced methylglyoxal 
modification of proteins and protected against kidney damage in these mice (Maher, 
Dargusch et al. 2011).  This compound appears to be a promising target of th  glyoxalase 
pathway.  Treatment of BALB/cJ mice with this compound could determine if elevated 
GLO1 could protect against the development of insensate neuropathy. 
Chapter 5: Mitochondrial Oxidative Phosphorylation Proteins Are Reduced 
Following In Vitro Methylglyoxal Treatment of Sensory Neurons 
 In the final study, cultured sensory neurons were treated with various 
concentrations of methylglyoxal to determine if oxidative phosphorylation complexes 
were targets of protein modification.  Cultured DRG neurons from C57BL/6 mice treated 
with 100 µM methylglyoxal showed significant reductions in three of four complexes 
measured.  However, sensory neurons from BALB/cByJ and BALB/cJ mie did not 
display alterations in protein expression following  vitro treatment with methylglyoxal.  
These differences could be attributable to a number of variables that need further 
investigation. 
 Since sensory neurons from C57BL/6 mice showed mitochondrial alterations, his 
model could be used to determine precisely the pathogenic and mechanistic consequences 
of mitochondrial dysfunction that is occurring in methylglyoxal treated cells.  In 
neuroblastoma cell lines, ATP production has been shown to be significantly reduced 
following methylglyoxal treatment that is probably a direct consequence of reduced 
electron transport chain proteins, although these lines also showed incrased cell death.  
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However, as previously discussed, reduced expression of oxidative phosphorylation 
proteins often results in a compensatory increase in reactive oxygen species and oxidative 
stress in certain tissue under hyperglycemic conditions.  Consequently, determining the 
precise mechanism by which altered mitochondrial proteins produce neuronal 
dysfunction is clearly worth studying. 
 Future experiments may also utilize primary sensory neuron cultures from both 
type I and type II diabetic mouse models to better understand the effects of methylglyoxal 
treatment.  Utilizing diabetic sensory neurons that have inherent mtabolic deficits could 
show more dramatic reductions in the expression of oxidative phosphorylation proteins 
following methylglyoxal treatment than nondiabetic sensory neurons.  Consequently, due 
to these inherent baseline differences, diabetic sensory neuron cultures may be more 
sensitive to reactive dicarbonyl treatment and near physiologic concentrations of 
methylglyoxal may be sufficient to alter the mitochondrial proteome. 
 New research suggests mitochondria are highly dynamic organelles that localize 
in sites of high energy demand in the sensory neuron including the cell body and in the 
axon, particularly in free nerve endings of the skin.  In vitro studies could isolate 
mitochondria from the perikyma and distal nerves to compare the expression of 
mitochondrial oxidative phosphorylation proteins, mitochondrial morphology, and ATP 
levels to determine if the axonal mitochondria are even more susceptible to protein 
alterations and energy depletion indicative of length-dependent damage following 
methylglyoxal treatment.  While mitochondria from the cell body are damaged, the 
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periphery may be more dependent on normal mitochondrial function and thus more 
susceptible to mitochondrial dysfunction as a result of high reactive dicarbonyls.  
 While in vitro methylglyoxal treatment provides insight into key pathogenic 
mechanisms, in vivo methylglyoxal treatment of nondiabetic and diabetic BALB/c mice 
would also be valuable.  Lumbar intrathecal injections of methylglyoxal would target the 
compound to the DRG that supply sensory innervation to the hindpaw.  This treatment 
would determine if alterations in mechanical thresholds can be achieved in treated 
nondiabetic mice and if treated diabetic mice have exacerbated signs of diabetic 
neuropathy. 
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